Dear Colleague,

We are proud to present our program for this 5th edition of Clinical Trials on Alzheimer’s Disease which will take place October 29-31, 2012 at the Grimaldi Forum in Monte Carlo with the support of the Monegasque Association for research on Alzheimer’s disease (AMPA)

Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s disease drugs is becoming essential to face up to this challenge. New pathways have been identified with biomarkers, facilitating novel trial designs for studies of tau-based therapies and other disease-modifying drugs including immunotherapy. However, methodological challenges continue to slow the development of specific new drug candidates. One of the objectives of the conference is to identify these hurdles and find ways to address them by bringing together world leaders in AD drug development to discuss solutions to the difficulties that have slowed the pace of progress, with a particular focus on clinical trial methodology.

Again this year CTAD is the perfect opportunity to hear about the clinical experiences of international teams, exchange with your peers on the difficulties and challenges of Alzheimer’s disease and take home some hands-on therapeutic and methodological tools to improve and reinforce your AD clinical trials teams. CME Credit are available from the University of California at San Diego (USCD).

We are very happy to welcome you to CTAD 2012!

Paul Aisen - Jacques Touchon - Bruno Vellas - Michael Weiner

The Monegasque Association for research on Alzheimer’s disease (AMPA) is a non-profit organization chaired by Catherine Pastor and Vice-President Prof. Alain Pesce, head of the Department of Geriatrics at the Princess Grace Hospital in Monaco. AMPA's mission is to support research on Alzheimer's disease, to sustain local initiatives for people with dementia and their caregivers, to raise awareness and disseminate information and expertise. Since 2008, AMPA also promotes international exchanges between scientists in order to increase knowledge and encourage innovative research.

www.ampa-monaco.com
# CONTENTS

**Program** ........................................................................................................... p. 2 - 14

Program at a glance .................................................................................................. p. 2 - 3

Monday, October 29\(^{th}\) ......................................................................................... p. 4 - 8

Tuesday, October 30\(^{th}\) ........................................................................................... p. 8 - 12

Wednesday, October 31\(^{st}\) ...................................................................................... p. 12 - 14

**Scientific Posters** ............................................................................................... p. 15 - 26

**Continuing Medical Education** ........................................................................ p. 27 - 28

**Faculty List** ......................................................................................................... p. 29 - 31

**Disclosure summary** .......................................................................................... p. 32 - 34

**Congress Venue** .................................................................................................. p. 35

**Privileged Supporters** ......................................................................................... p. 36
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00 - 8.15 a.m</td>
<td>WELCOME BY THE ORGANIZING COMMITTEE</td>
</tr>
<tr>
<td>8.15 - 8.45 a.m</td>
<td>KEYNOTE 1: 5-year experience in AD clinical trials as member of the Medical Committee for Medicinal Products for Human Use and CNS working group within the EMEA</td>
</tr>
<tr>
<td>8.45 - 9.45 a.m</td>
<td>Symposium 1: Harmonizing Regulatory Requirements to Benefit Future Alzheimer’s Disease Patients</td>
</tr>
<tr>
<td>9.45 - 10.45 a.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>11.15 - 12.15 p.m</td>
<td>Symposium 2: Bapineuzumab IV Phase 3 Results</td>
</tr>
<tr>
<td>1.30 - 2.30 p.m</td>
<td>Symposium 3: Effects of Apolipoprotein E Isoforms on Patient Characteristics and Trial Outcomes in Light of Recent Phase 3 results: Stratified Medicine for Alzheimer’s Disease Drug Development</td>
</tr>
<tr>
<td>2.30 - 4.00 p.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>4.30 - 6.10 p.m</td>
<td>UPDATE ON CLINICAL TRIALS 1</td>
</tr>
<tr>
<td>7.00 p.m</td>
<td>WELCOME RECEPTION with the support of AMPA</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Tuesday, October 30th</strong></td>
<td></td>
</tr>
<tr>
<td>8.00 - 8.45 a.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>8.45 - 9.45 a.m</td>
<td>Symposium 4: Enrichment Approaches in Predementia AD Clinical Trials</td>
</tr>
<tr>
<td>9.45 - 10.25 a.m</td>
<td>UPDATE ON CLINICAL TRIALS 2</td>
</tr>
<tr>
<td></td>
<td>Coffee Break and poster sessions</td>
</tr>
<tr>
<td>11.00 - 12.00 p.m</td>
<td>Symposium 5: Solanezumab Phase 3 results: Implications for Alzheimer’s disease modification</td>
</tr>
<tr>
<td></td>
<td>Lunch Break and poster sessions</td>
</tr>
<tr>
<td>1.00 - 3.00 p.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>3.00 - 4.00 p.m</td>
<td>Symposium 6: Modeling the Course of AD: Contributions to Better Clinical Trials</td>
</tr>
<tr>
<td></td>
<td>Coffee Break and poster sessions</td>
</tr>
<tr>
<td>4.30 - 5.30 p.m</td>
<td>Symposium 7: MAPT (Multidomain Alzheimer Preventive Trial) imaging data</td>
</tr>
<tr>
<td>5.30 - 6.00 p.m</td>
<td>KEYNOTE 2: New design for symptomatic treatment of AD</td>
</tr>
<tr>
<td>6.00 - 6.30 p.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td><strong>Wednesday, October 31st</strong></td>
<td></td>
</tr>
<tr>
<td>8.00 - 9.00 a.m</td>
<td>UPDATE ON CLINICAL TRIALS 3</td>
</tr>
<tr>
<td>9.00 - 10.00 a.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td></td>
<td>Coffee Break and poster sessions</td>
</tr>
<tr>
<td>10.30 - 12.30 p.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
</tbody>
</table>
Monday, October 29th

8.00 - 8.15 a.m | WELCOME BY THE ORGANIZING COMMITTEE
Paul Aisen, University of California at San Diego, USA, Jacques Touchon, Montpellier University Hospital, INSERM U1061, France, Bruno Vellas, Toulouse University Hospital, France, Mike Weiner, University of California at San Francisco, USA

8.15 - 8.45 a.m | KEYNOTE 1: 5-year experience in AD clinical trials as member of the Medical Committee for Medicinal Products for Human Use and CNS working group within the EMEA
Cristina Sampaio, Scientific Expert, EMEA

8.45 - 9.45 a.m | Symposium 1: Harmonizing Regulatory Requirements to Benefit Future Alzheimer’s Disease Patients
Chairman: Daniel Perry (1)

Presenters: Diane Stephenson (2), Karl Broich (3)
(1) ACT-AD Coalition, Alliance for Aging Research, USA, (2) Coalition Against Major Diseases, Critical Path Institute, USA
(3) Federal Institute for Drugs and Medical Devices (BfArM)

9.45 - 10.45 a.m | ORAL COMMUNICATIONS
Moderators: M.Egan, H.Hampel

9.45 - 10.00 a.m OC1 - Is the Dementia of Alzheimer’s Disease due to the Toxicity of β-Amyloid or Tau? The Implications of this Question for Drug Discovery
Jordan Holtzman, University of Minnesota, Minneapolis, MN, USA

10.00 - 10.15 a.m OC2 - Potential of Human analogue of Morris Water Maze in translational medicine and the assessment of therapeutic response
John Harrison (2,4,5), Jan Laczo (1,2), Manfred Windisch (2,3), Jakub Hort (1,2)
(1) Memory Disorders Clinic, Department of Neurology, Charles University in Prague, 2nd Medical Faculty and University Hospital Motol, Prague, Czech Republic, (2) Polyhymnia Translational Research, London, UK, (3) JSW-Lifesciences GmbH, Grambach-Graz, Austria, (4) Metis Cognition Ltd., Kilmington, UK, (5) Dept. of Medicine, Imperial College, London, UK

10.15 - 10.30 a.m OC3 - Assumptions of mortality have a great impact on the cost-effectiveness of disease-modifying drugs in AD
Anders Sköldunger (1), Kristina Johnell (1), Bengt Winblad (2), Anders Wimo (2)
(1) Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden, (2) KI-Alzheimer’s Disease Research Center, Karolinska Institutet, Huddinge, Sweden
Monday, October 29th  Continued

10.30 - 10.45 a.m  OC4 -  The Novel BACE Inhibitor MK-8931 Dramatically Lowers CSF Aβ Peptides in Healthy Subjects Following Single and Multiple Dose Administration  
   Michael F. Egan (1), Mark S Forman (1), John Palcza (1), Jack Tseng (1), Jos Leempoels (2), Steven Ramael (2), David Han (3,4),  
   Stanford Jhee (3), Larry Ereshefsky (3,5), Michael Tanen (1), Omar Laterza (1), Marissa Dockendorf (1), Gopal Krishna (1), Lei  
   Ma (1), John A Wagner (1), Matthew D Troyer (1)  
   (1) Merck, Whitehouse Station, NJ, USA, (2) SGS Life Science Services, Antwerpen, Belgium, (3) Parexel International Early Phase, Glendale,  
   CA, USA, (4) California Clinical Trials Medical Group, Glendale, CA, (5) University of Texas Health Science Center, San Antonio, TX

10.45 - 11.15 a.m  Coffee Break and poster sessions

11.15 - 12.15 p.m  Symposium 2: Bapineuzumab IV Phase 3 results  
   Chairman: Philip Scheltens (1)  
   Presenters: Reisa Sperling (2), Stephen Salloway (3), Nick Fox (4)  
   (1) VU University Medical Center, Alzheimer Center, Amsterdam, the Netherlands, (2) Brigham & Women’s Hospital, Boston, MA, USA  
   (3) Butler Hospital, Providence, RI, USA, (4) UCL, Institute of Neurology, London, United Kingdom

12.15 - 1.30 p.m  Lunch Break and poster sessions

1.30 - 2.30 p.m  Symposium 3: Effects of Apolipoprotein E Isoforms on Patient Characteristics and Trials Outcomes in Light of Recent Phase 3 Results: Stratified Medicine for Alzheimer’s Disease Drug Development  
   Chairman: Lon S. Schneider, University of Southern California, Los Angeles, CA, USA

1.30 - 1.50 p.m  • The neurobiology and impact of apoE4 and apoE2 carriage on clinical trials  
   Terry Goldberg, Hofstra North Shore LIJ School of Medicine, Manhasset, New York, USA

1.50 - 2.10 p.m  • Relation of apoE to brain structure and function in Alzheimer’s disease and aging  
   Michela Pievani, IRCCS Fatebenefratelli Brescia, Brescia, Italy

2.10 - 2.30 p.m  • Simulating apoE stratified medicine trials in Alzheimer’s disease  
   Lon S. Schneider (1), Richard Kennedy (2), Gary Cutter (2)  
   (1) Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA, (2) School of Public Health, University of Alabama,  
   Birmingham, Alabama, USA
2.30 - 4.00 p.m  ORAL COMMUNICATIONS

Moderators: G. Frisoni, B. Winblad

2.30 - 2.45 p.m  OC5 - Measuring cognitive change from mild cognitive impairment to prodromal Alzheimer disease

T. Mura (1,2,3,4), C. Proust-Lima (5,6), H. Jaccmin-Gadda (5,6), T. N. Akbaraly (1,2,7), B. Dubois (8), C. Berry (1,2,9)

(1) INSERM U1061, Neuropsychiatrie - Recherche Epidemiologique et Clinique, Montpellier, France, (2) Université Montpellier I, Montpellier, France, (3) Département d’Information Médicale, Centre d’Investigation Clinique, CHU Montpellier, Montpellier, France, (4) INSERM, CIC 1001, Montpellier, France, (5) INSERM U897, Equipe de Biostatistique, Centre de Recherche en Epidemiologie et Biostatistique, Bordeaux, France, (6) Université Bordeaux Segalen, ISPED, Bordeaux, France, (7) Department of Epidemiology and Public Health, University College London, London, United Kingdom, (8) INSERM-UPMC UMR S 975, Institut de la Mémoire et de la Maladie d’Alzheimer, ICM, APHP, Salpêtrière Hospital, University Paris 6, Paris, France, (9) CMRR Languedoc Roussillon, service de Neurologie, CHU Montpellier, Montpellier, France

2.45 - 3.00 p.m  OC6 - Long-Term Longitudinal Biomarker Trials in Subjects at Genetic Risk of Developing Alzheimer’s Disease: the GEPARD-AD Studies

Joel Ross (1), Paul M. Thompson (2), Rachelle S. Doody (3), Pierre N. Tariot (4), Eric M. Reiman (4), Jessica Langbaum (4), Lon S. Schneider (5), Ugo Lucca (6), Enrico Frigeri (7), Francesco Fiorentini (7), Luciana Giardino (6), Laura Calzà (6), Dottie Norris (9), Helen Cicirello (9), Daniela Casula (9), Bruno P. Imbimbo (9)

(1) Memory Enhancement Center of America, 4 Industrial Way West, Eatontown, NJ, USA, (2) Laboratory of Neuro Imaging, Dept. of Neurology, UCLA School of Medicine, Los Angeles, CA, USA, (3) Alzheimer’s Disease and Memory Disorders Center, Baylor College of Medicine, Department of Neurology, Houston, TX, USA, (4) Banner Alzheimer’s Institute, AZ, USA, (5) University of Southern California Keck School of Medicine, Los Angeles, CA, USA, (6) Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy

(7) Accelera Srl, Nerviano, Italy, (8) Health Sciences and Technologies - Interdepartmental Center for Industrial Research (HST-ICIR), University of Bologna, Ozzano Emilia, Bologna, Italy, (9) Research & Development, Chiesi Pharmaceuticals Inc., Rockville, MD 20850, USA

3.00 - 3.15 p.m  OC7 - The Dominantly Inherited Alzheimer’s Network Trials

Randall Bateman, on behalf of the Dominantly Inherited Alzheimer Network

3.15 - 3.30 p.m  OC8 - Definition of Harmonized Protocol for Hippocampal Segmentation

Marina Boccardi (1), Martina Bocchetta (1,2), Lianna Apostolova (3), Josephine Barnes (4), George Bartzokis (5), Gabriele Corbetta (1), Charles DeCarli (6), Leyla DeToledo-Morrell (7), Michael Firbank (8), Rossana Gandola (1), Lotte Gerritsen (9), Wouter Henneman (10), Ronald J. Killiany (11), Nikolai Malychkin (12), Patrizio Pasqualetti (2), Jens C. Pruessner (13), Alberto Redolfi (1), Nicolas Robitalle (14), Hilkka Soininen (15), Daniele Tolomeo (1), Lei Wang (16), Craig Watson (17), Henrikje Wolf (18), Simon Duchesne (14), Clifford R. Jack Jr (19), Giovanni B. Frisoni (1)

(1) LENITEM (Laboratory of Epidemiology, Neuroimaging and Telemedicine) IRCCS – S. Giovanni di Dio – Fatebenefratelli Brescia, Italy, (2) AFAr – Associazione Fattenefratelli per la Ricerca, Rome, Italy, (3) Laboratory of Neuromaging, David Geffen School of Medicine, University of California, Los Angeles, CA, (4) Dementia Research Centre, UCL Institute of Neurology, University College London, London, UK, (5) Department of Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, (6) Department of Neurology, University of California, Davis, CA, (7) Department of Neurological Sciences, Rush University, Chicago, Illinois, (8) Institute for Ageing and Health, Newcastle University, Wolfson Research Centre, Newcastle, UK, (9) Karolinska Institute, Stockholm, Sweden, (10) Department of Radiology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands, (11) Department of Anatomy and Neurobiology, Boston University School of Medicine, MA, USA
Monday, October 29\textsuperscript{th}  Continued

2.30 - 4.00 p.m  **ORAL COMMUNICATIONS**  Continued

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 3.30 - 3.45 p.m | **OC9** - Robustness of Automated Hippocampal Volumetry across MR Field strengths and Same-Day Repeat Scans  
Robin Wolz\(^{(1,2)}\), Adam J. Schwarz\(^{(3)}\), Peng Yu\(^{(3)}\), Pat Cole\(^{(4)}\), Daniel Rueckert\(^{(1,2)}\), David Raunig\(^{(5)}\), Derek Hill\(^{(1)}\)  
\(^{(1)}\) IXICO Ltd, London, UK, \(^{(2)}\) Imperial College London, London, UK, \(^{(3)}\) Eli Lilly and Company, Indianapolis IN, USA, \(^{(4)}\) Cole Consulting, NJ, USA, \(^{(5)}\) Icon Medical Imaging, Warrington PA, USA |
| 3.45 - 4.00 p.m | **OC10** - Disentangling the normal aging from the pathological Alzheimer’s disease progression on structural MR images  
Marco Lorenzi\(^{(1,2)}\), Nicholas Ayache\(^{(2)}\), Xavier Pennec\(^{(2)}\), Giovanni B. Frisoni\(^{(1)}\), and the Alzheimer’s Disease Neuroimaging Initiative (ADNI)  
\(^{(1)}\) IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy, \(^{(2)}\) Asclepios research project, INRIA Sophia antipolis, France |

4.00 - 4.30 p.m  **UPDATE ON CLINICAL TRIALS 1**
**Moderators:** R. Doody, J. Touchon

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 4.30 - 4.50 p.m | 1 - Safety and Efficacy of Solanezumab in Patients with Mild to Moderate Alzheimer’s Disease: Results from Phase 3  
Rachelle S. Doody, Baylor College of Medicine - Department of Neurology, Houston, Texas, USA |
| 4.50 - 5.10 p.m | 2 - The Effects of ELND005 (Scyllo-inositol) on Agitation/Aggression in AD Dementia: Results from a 78 week Phase 2 Study in Mild to Moderate AD  
Susan Abushakra\(^{(1)}\), Constantine Lyketsos\(^{(2)}\), Gerald Crans\(^{(1)}\), Priya Nadkarni\(^{(1)}\), Chito Hernandez\(^{(1)}\), Bruno Vellas\(^{(3)}\)  
\(^{(1)}\) Elan Pharmaceuticals, Inc., South San Francisco, CA, USA, \(^{(2)}\) Johns Hopkins University, Baltimore, MD, USA, \(^{(3)}\) University of Toulouse, Toulouse, France |
| 5.10 - 5.30 p.m | 3 - ERP as biomarkers for Preclinical-AD  
Karim Bennys\(^{(1)}\), Audrey Gabelle\(^{(1)}\), Jacques Touchon\(^{(1,2)}\), \(^{(1)}\) Department of Neurology, Memory Research Resource Center for Alzheimer’s Disease, University Hospital of Montpellier, France, \(^{(2)}\) Inserm U1061, Montpellier, France |
Monday, October 29th

4.30 - 6.10 p.m UPDATE ON CLINICAL TRIALS

5.30 - 5.50 p.m

4 - The SKT short cognitive performance test in pre-clinical and dementia stages of neurocognitive disorders
Mark Stemmler, University of Erlangen-Nuremberg, Germany

5.50 - 6.10 p.m

5 - Applicability of new criteria for Clinical Trials in AD
Bruno Dubois (1), Paul Aisen (2)
(1) Dementia Research Center, Salpêtrière University Hospital, Paris, France, (2) Department of Neurosciences, UCSD, San Diego, USA

7.00 p.m

Bus departure for the WELCOME RECEPTION
with support of The Monegasque Association for research on Alzheimer’s disease (AMPA) - Catherine PASTOR

Tuesday, October 30th

8.00 - 8.45 a.m ORAL COMMUNICATIONS

OC11 - Bayesian adaptive trial design: A new approach for Phase 2 clinical trials in Alzheimer’s disease
Andrew Satlin (1), Veronika Logovinsky (1), Jinping Wang (1), Chad Swanson (1), Scott Berry (2), Don Berry (2)
(1) Eisai Inc., Neuroscience Product Creation Unit, NJ, (2) Berry Consultants, LLC, Austin, TX USA

OC12 - A New Tool for Optimizing Responsiveness to Decline in Early AD
Suzanne Hendrix (1), Veronika Logovinsky (2), Carlos Perdomo (2), Jinping Wang (2), Andrew Satlin (2)
(1) Pentara Corporation, Salt Lake City, UT, 84109, (2) Eisai Inc., Neuroscience Product Creation Unit, Woodcliff Lake, NJ

OC13 - Effects of age and APOE ε4 on the course of clinical and structural decline in Alzheimer disease
Dominic Holland (1), Linda K McEvoy (2), Rahul S. Desikan (2), Anders M Dale (1,2)
(1) Department of Neurosciences, (2) Department of Radiology, University of California, San Diego, CA, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8.45 - 9.45 a.m | **Symposium 4 : Enrichment Approaches in Predementia AD Clinical Trials**  
Chairman : Jesse Cedarbaum (1) |
| 8.55 - 9.20 a.m | Predementia AD: Qualifying CSF and PET biomarkers for clinical trial use  
Remy Cahn (3) |
| 9.25 - 9.45 a.m | Experience with CSF and PET Biomarkers for Enrichment of Predementia AD Trials  
Christopher van Dyck (3) |
| 9.45 - 10.25 a.m | **UPDATE ON CLINICAL TRIALS 2**  
Moderators : E. Giacobini, L. Buée |
| 9.45 - 10.05 a.m | 6 - Harmonisation of reporting standards for studies of diagnostic test accuracy in dementia : the STARDdem (STAndards for the Reporting of Diagnostic accuracy studies-Dementia) criteria  
Description of STARDdem process and Validation Study  
Rupert McShane (1), Anna Noel-Storr (1), Leon Flicker (2), Craig W Ritchie (3), Gordon Wilcock (4), STARDdem Working Group  
(1) Cochrane Dementia and Cognitive Improvement Group, University of Oxford, United Kingdom, (2) Geriatric Medicine, University of Western Australia  
(3) Old age psychiatry, Imperial College, London, (4) Clinical Geratology, University of Oxford |
| 10.05 - 10.25 a.m | 7 - Is the Beta-Amyloid cascade hypothesis dead ? If so, can it be resuscitated ?  
Ezio Giacobini, University of Geneva, Faculty of Medicine, Department of geriatrics |
| 10.25 - 11.00 a.m | Coffee Break and poster sessions |
| 11.00 - 12.00 p.m | **Symposium 5 : Solanezumab Phase 3 results: Implications for Alzheimer’s disease modification**  
Chairman : Eric Siemers, Eli Lilly, USA |
<p>| Noon to 1 p.m | Lunch Break and poster sessions |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.00 - 1.15 p.m</td>
<td>OC14</td>
<td>Enrichment, Stratification, and Outcome Measures for Predementia Alzheimer Disease Clinical Trials</td>
<td>Dominic Holland (1), Linda K McEvoy (2), Rahul S. Desikan (3), Anders M. Dale (1,2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(1) Department of Neurosciences, (2) Department of Radiology, University of California, San Diego, CA, USA</td>
</tr>
<tr>
<td>1.15 - 1.30 p.m</td>
<td>OC15</td>
<td>Missing data in ADCS clinical trials</td>
<td>Michael Donahue (1,2), Anthony Gamst (1,2), Rema Raman (1,2), Ronald Thomas (2), Paul Aisen (2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(1) Department of Biostatistics &amp; Bioinformatics, University of California, San Diego, USA, (2) Department of Neurosciences, University of California, San Diego, USA</td>
</tr>
<tr>
<td>1.30 - 1.45 p.m</td>
<td>OC16</td>
<td>Souvenaid preserves brain function in patients with mild Alzheimer’s disease: results from a randomised controlled study</td>
<td>Elisabeth CW van Straaten (1), Hanneke de Waal (2), Marieke M. Lansbergen (3), Philip Scheltens (2), Cornelis J. Stam (1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(1) Department of Clinical Neurophysiology, VU University Medical Centre, Amsterdam, The Netherlands, (2) Department of Neurology and Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands, (3) Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands</td>
</tr>
<tr>
<td>1.45 - 2.00 p.m</td>
<td>OC17</td>
<td>The Kinase PKR: a diagnostic and therapeutic target in Alzheimer’s disease</td>
<td>Jacques Hugon, François Mouton-Liger, Julien Dumurgier, Claire Paquet</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Memory Center Lariboisiere Hospital APHP, University Diderot Paris France and Institut du Fer a Moulin, Inserm U 839 Paris France</td>
</tr>
<tr>
<td>2.00 - 2.15 p.m</td>
<td>OC18</td>
<td>Towards Standardization of CSF Biomarkers: A Multi-Site Study Using Validated Assays for Aβ42 and Tau</td>
<td>Robert M. Umek, David H. Stewart, Jill M. Dunty, Nyssa L. Puskar, Pankaj Oberoi, Jacob N. Wohlstader</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MUSEO SCALE DISCOVERY, Gaithersburg, MD 20877 USA</td>
</tr>
<tr>
<td>2.15 - 2.30 p.m</td>
<td>OC19</td>
<td>Are neuropsychological tests such as those used in ADNI suitable for long-term trials of cognition enhancers for preclinical Alzheimer</td>
<td>Keith Wesnes (1,2), Lon Schneider (3), Keck School of Medicine of the University of Southern California, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(1) Bracket Global, Goring, UK, (2) Swinburne University, Melbourne, Australia, (3) Keck School of Medicine of the University of Southern California, USA</td>
</tr>
<tr>
<td>2.30 - 2.45 p.m</td>
<td>OC20</td>
<td>Phase II trial of Metformin in Amnestic MCI</td>
<td>Jose A. Luchsinger (1), Jennifer Manly (2), Jason Steffener (2), Emilia Bagiella (3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(1) Department of Medicine, Columbia University Medical Center, New York, New York, USA, (2) Gertrude H. Sergievsky Center, Columbia University Medical Center, New York, New York, USA, (3) Biostatistics Center for Clinical Trials Management, Mt. Sinai School of Medicine, New York, NY, USA</td>
</tr>
<tr>
<td>2.45 - 3.00 p.m</td>
<td>OC21</td>
<td>γ-secretase-linked clinical trials failures: An amyloid cascade hypothesis rebuttal or just experimental pitfalls unmasked?</td>
<td>Frédéric Checler, CNRS, Sophia Antipolis, France</td>
</tr>
</tbody>
</table>
### Tuesday, October 30th  
**Continued**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| **3.00 - 4.00 p.m** | **Symposium 6 : Modeling the Course of AD: Contributions to Better Clinical Trials**  
**Chairman : René Spiegel, Memory Clinic, Department of Geriatrics, University Hospital, Basel, Switzerland** |
| **3.00 - 3.20 p.m** | • Predicting Progression of AD: Understanding the Variance  
**Rachel S. Doody** (1), **Chan Wen** (2), **Pavlik Valory** (1), **Paul Massman** (1,3), **Eveleen Darby** (1), **Susan Rountree** (1)  
(1) Baylor College of Medicine - Department of Neurology, Houston, Texas, USA, (2) University of Texas Health Science Center, Houston, Texas, USA, (3) University of Houston, Texas, USA |
| **3.20 - 3.40 p.m** | • Creating a New Composite Score for Optimizing Responsiveness to Decline in Early AD and Very Early AD  
**Suzanne Hendrix**, Pentara Corporation, Salt Lake City, UT, USA |
| **3.40 - 4.00 p.m** | • The Placebo Group Simulation Approach (PGSA): An Alternative to Long-term Placebo-controlled Trials  
**René Spiegel** (1), **Manfred Berres** (2), **André R. Miserez** (3), **Andreas U. Monsch** (1)  
(1) Memory Clinic, Department of Geriatrics, University Hospital, Basel, Switzerland, (2) University of Applied Sciences Koblenz, RheinAhr Campus, Remagen, Germany, (3) Diagene Laboratories Inc., Reinach, Switzerland |
| **4.00 - 4.30 p.m** | Coffee Break and poster sessions |
| **4.30 - 5.30 p.m** | **Symposium 7 : MAPT (Multidomain Alzheimer Preventive Trial) Imaging (MRI, FDG-PET, amyloid-PET) data**  
**Chairmen : Bruno Vellas** (1), **Jacques Touchon** (2), **Mike Weiner** (3)  
(1) Toulouse University Hospital, France, (2) Montpellier University Hospital, Inserm U1061, Montpellier, France, (3) University of California San Francisco, USA |
| **4.30 - 4.45 p.m** | • MAPT Trial Design  
**Bruno Vellas**, Toulouse University Hospital, France, Gerontopole, Inserm U1027 |
| **4.45 - 5.00 p.m** | • One year longitudinal study of FDG-PET in MAPT  
**Thierry Voisin**, Toulouse University Hospital, France |
| **5.00 - 5.15 p.m** | • High prevalence of amyloid positive PET in pre frail and frail older adults  
**Pierre Payoux**, Toulouse University Hospital, France |
| **5.15 - 5.30 p.m** | • M.R.I. Data at baseline  
**Carole Dufouil**, Bordeaux University Hospital, France |
### Tuesday, October 30th

**5.30 - 6.00 p.m**  
**KEYNOTE 2**  
**New design for symptomatic treatment of AD**  
**Lon S. Schneider, University of Southern California, Los Angeles, CA, USA**

**6.00 p.m**  
**ORAL COMMUNICATIONS**  
**Moderators**: S. Andrieu, R. Spiegel

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 6.00 - 6.15 p.m | OC22 - **Statistical Power of a Preventive Trial in Alzheimer's Disease, about the GuidAge Study**  
**Bruno Scherrer** (1), Philippe Garnier (2), Hélène Mathiex-Fortunet (2), Sandrine Andrieu (3), Bruno Vellas (4)  
(2) Ipsen, Boulogne, France  
(2) Inserm UMR 1027, Toulouse, France  
(4) Gérontopole, Toulouse, France |
| 6.15 - 6.30 p.m | OC23 - **Detecting And Intervening In Mild Cognitive Impairment: Is It Cost Effective?**  
**Jennifer H Barnett** (1,2), Lily Lewis (3), Andrew Blackwell (1,2), Matthew Taylor (3)  
(1) Cambridge Cognition, Cambridge UK  
(2) University of Cambridge Department of Psychiatry, UK  
(3) York Health Economics Consortium, University of York, UK |

### Wednesday, October 31st

**8.00 - 9.00 a.m**  
**UPDATE ON CLINICAL TRIALS 3**  
**Moderators**: P. Robert, M. Weiner

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 8.00 - 8.20 a.m | 8 - **Challenges and Perspectives in Designing and Conducting Studies in Alzheimer's disease (AD)**  
**Christian Yavorsky**, CROnos CCS, Hamilton, NJ, USA |
| 8.20 - 8.40 a.m | 9 - **Improving Detection of Treatment Effect Through Better Methodology**  
**William R. Shankle** (1,2), Ali Reza Atri (3,4), Michael Rafii (5,6,7)  
(1) Shankle Clinic, Newport Beach, CA USA, (2) Memory and Cognitive Disorders Program, Hoag Neurosciences Institute; Medical Care Corporation; Dept of Cognitive Sciences, University of California at Irvine, CA, USA, (3) Clinical Programs, GRECC, ENRM VA Bedford Medical Center, USA, (4) Memory Disorders Unit & MA Alzheimer’s Disease Research Center; Massachusetts General Hospital; Harvard Medical School, USA, (5) Memory Disorders Clinic at University of California at San Diego Perlman Ambulatory Care Center, San Diego, CA, USA, (6) Dept of Neurosciences at the University of California, San Diego, Alzheimer’s Disease Cooperative Study, USA, (7) Shiley-Marcos Alzheimer’s Disease Research Center, USA |
| 8.40 - 9.00 a.m | 10 - **How imaging is used to select subjects and determine therapeutic and adverse effects in Alzheimer’s treatment trials**  
**Michael Weiner**, University of California San Francisco, USA |
**Wednesday, October 31st**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00 - 10.00 p.m</td>
<td>ORAL COMMUNICATIONS</td>
<td>Clinical trials and Ethical issues: new challenges, new perspectives</td>
<td>Federico Palermiti, Catherine Pastor, AMPA, Monte Carlo</td>
</tr>
</tbody>
</table>
| 9.00 - 9.15 a.m | OC24    | A Multi-Center Clinical Trial to Validate Event-Related Potentials as Useful Biomarkers for Early Detection of Alzheimer’s disease | K.C. Fadem (1), Marco Cecchi (1), Sarah Berg (1), Charles Smith (2), Gregory Jicha (2), Paul Solomon (3), Carl Sadowsky (4), P.Murali Doraiswami (5), Steven Arnold (6)  
(1) Neurontex, KY, USA, (2) Neurology Department, University of Kentucky, KY, USA, (3) The Memory Clinic, VT, USA, (4) Premiere Research Institute, FL, USA, (5) Psychiatry Department, Duke University, NC, USA, (6) Psychiatry Department, University of Pennsylvania, PA, USA |
| 9.15 - 9.30 a.m | OC25    | Positive effects on cognition and clinical function in mild to moderate alzheimer’s disease patients with a selective alpha-7 nicotinic partial agonist: interpretation of effects based on a pk/pd model | DC. Hilt (1), M. Gawryl (1), G. Koenig (1), N. Dgetluck (1), J. Harrison (2), H.J. Moebius (1), G. Loewen (1), EVP-6124-010 Study Group  
(1) EnVivo Pharmaceuticals, Watertown, MA, USA, (2) Metis Cognition Ltd, UK |
| 9.30 - 9.45 a.m | OC26    | pS422 Tau-immunotherapy in THY-Tau22 transgenic mice                  | Luc Buée, Laetitia Troquier, Philippe Lassalle, David Blum, Inserm U837 - Alzheimer & Tauopathies, Faculty of Medicine, Research Department, Lille, France |
| 9.45 - 10.00 a.m | OC27    | Stability of symmetric atrophy measurement algorithms: impacts on interim and final analyses | D.M. Cash (1,2), J. Bartlett (1,3), S. Finnegan (1), K.K. Leung (1), G.R. Ridgway (4), M.J. Cardoso (5), J.M. Schott (1), S. Ourselin (1,2), N.C. Fox (1)  
(1) Dementia Research Centre, UCL Institute of Neurology, University College London The Alzheimer’s Disease Neuroimaging Initiative, (2) Centre for Medical Image Computing, Department of Computer Science, University College London, (3) Department of Medical Statistics, London School of Hygiene and Tropical Medicine, (4) Wellcome Trust Centre for Neuroimaging, UCL Institute of Neurology |
| 10.00 - 10.30 a.m |       | Coffee Break and poster sessions                                      |                                                                                                                                          |
| 10.30 - 12.30 p.m | ORAL COMMUNICATIONS | Outpatients with severe Alzheimer’s disease participating in an observational study: Baseline results of the GERAS study | Catherine Reed (1), Josep Maria Argimon (2), Mark Belger (1), Giuseppe Bruno (3), Richard Dodel (4), Michael Happich (5), Josep Maria Haro (6), Roy W. Jones (7), Bruno Vellas (8), Anders Wimo (9)  
(1) Eli Lilly and Company Limited, Windlesham, UK, (2) Servei Català de la Salut, Barcelona, Spain, (3) University of Rome «Sapienza», Rome, Italy, (4) Philadelphia-University, Marburg, Germany, (5) Lilly Deutschland GmbH, Bad Homburg, Germany, (6) Parc Santal Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain, (7) The RICE Centre, Royal United Hospital, Bath, UK, (8) Toulouse University Hospital, Toulouse, France, (9) Karolinska Institute, Stockholm, Sweden |
**ORAL COMMUNICATIONS - Continued**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00 - 11.15 a.m</td>
<td>OC30</td>
<td>Level of education, risk of Alzheimer’s disease, and cognitive decline in the GuidAge prevention trial</td>
<td>Nicola Coley (1,2), Grégory Guernec (1), Bruno Vellas (1,2,3), Sandrine Andrieu (1,2,3,4) and the Guidage study group</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(1) INSERM, U1027, Toulouse, France, (2) Université de Toulouse III, Toulouse, France, (3) Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, (4) Département d’Épidémiologie et Santé Publique, Centre Hospitalier Universitaire de Toulouse, Toulouse, France</td>
</tr>
<tr>
<td>11.15 - 11.30 a.m</td>
<td>OC31</td>
<td>Repurposing cardiovascular drugs as Alzheimer’s disease modifying agents</td>
<td>Giulio Maria Pasinetti (1), Paul Rosenberg (2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(1) Department of Neurology, Mount Sinai School of Medicine, New York, USA, (2) Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, USA</td>
</tr>
<tr>
<td>11.30 - 11.45 a.m</td>
<td>OC32</td>
<td>Comparison of interim results after one and two years of treatment of ASCOMALVA TRIAL between a cholinesterase inhibitor and choline alphoscerate on cognitive deficits in Alzheimer’s disease associated with cerebrovascular impairment</td>
<td>Francesco Amenta (1), Anna Carotenuto (1), Raffaele Rea (1), Enea Traini (1), Angiola M. Fasanaro (2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(1) Center of Clinical Research, telemedicine and telepharmacy, University of Camerino, Italy, (2) Evaluation Department for Alzheimer’s Disease and other Neurogenerative disease, National University Hospital A. Cardarelli, Napoli, Italy</td>
</tr>
<tr>
<td>11.45 - 12.00 p.m</td>
<td>OC33</td>
<td>Translating Cognitive Performance to Functional Ability in Alzheimer’s, Lewy Body, Cerebrovascular, and Frontal Lobe Diseases</td>
<td>William R. Shankle (1,3,9), Junko Hara (1,2), Barry Reisberg (4), Michael Lee (5), James Pooley (8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(1) Shankle Clinic, Newport Beach, CA, USA, (2) Medical Care Corporation, Newport Beach, CA, USA, (3) Hoag Neurosciences Institute, Newport Beach, CA, USA, (4) Aging &amp; Dementia Research Center, New York University, New York, USA, (5) Dept. of Cognitive Sciences, University of California at Irvine, Irvine, CA, USA, (8) Dept. of Cognitive Sciences, University of California at Irvine, Irvine, CA, USA</td>
</tr>
<tr>
<td>12.00 - 12.15 p.m</td>
<td>OC34</td>
<td>Deregulation of Cdk5 activity and neurodegeneration induced by hyperphosphorylation of neuronal cytoskeletal proteins is inhibited by peptides derived from its activator p35; A novel approach to rescue the pathology induced by deregulation of kinases</td>
<td>Harish C. Pant, NINDS / NIH, Bethesda, MD, USA</td>
</tr>
<tr>
<td>12.15 - 12.30 p.m</td>
<td>OC35</td>
<td>Disease-Modifying Power Estimation for TauRx Global Phase 3 Trial Program in AD with Tau-Aggregation Inhibitor LMTX</td>
<td>Claude M. Wischik, Damon J. Wischik, TauRx Therapeutics, USA</td>
</tr>
</tbody>
</table>
SCIENTIFIC POSTERS

For your convenience posters are classified by themes and numbered accordingly:

<table>
<thead>
<tr>
<th>THEMES</th>
<th>Posters</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials : Methodological aspects</td>
<td>P1 through P12</td>
<td>p.16 to 17</td>
</tr>
<tr>
<td>Clinical trials Assessment Tools</td>
<td>P13 through P23</td>
<td>p.17 to 18</td>
</tr>
<tr>
<td>Therapeutic trials in AD</td>
<td>P24 through P35</td>
<td>p.18 to 19</td>
</tr>
<tr>
<td>Fundamental Research for AD clinical trials</td>
<td>P36 through P42</td>
<td>p.20</td>
</tr>
<tr>
<td>Biomarkers/Imaging in AD clinical trials</td>
<td>P43 through P63</td>
<td>p.21 to 23</td>
</tr>
<tr>
<td>Nutrition and Alzheimer’s Disease</td>
<td>P64 through P71</td>
<td>p.23 to 24</td>
</tr>
<tr>
<td>Miscellaneous in clinical trials</td>
<td>P72 through P88</td>
<td>p.24 to 25</td>
</tr>
</tbody>
</table>
### SCIENTIFIC POSTERS

**Clinical Trials: Methodological aspects**

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>Meta-Analysis for Behavioral and Neuropsychiatric Symptoms in Alzheimer’s disease (AD) Clinical Trials</td>
<td>Kaori Ito, Sima Ahadieh, Peter Lockwood, Thomas Tensfeldt, Brian Corrigan</td>
<td>Pfizer Inc, Primary Care Business Unit, Groton, CT, USA</td>
</tr>
<tr>
<td>P2</td>
<td>Characteristics of Alzheimer’s patients participating in research within the French National Alzheimer Bank Network</td>
<td>Karim Tifratene (1,2), Franck Leduff (1), Christian Pradier (1), Malthilde Laye (2), Roland Chevrier (1), Philippe Robert (2)</td>
<td>(1) Public Health Department, Nice University Hospital, France, (2) CMRR, EA CobTeK, Nice University</td>
</tr>
<tr>
<td>P3</td>
<td>Clinical background of participants of clinical trials on Alzheimer’s disease is different from that of actual patients.</td>
<td>Motoki Yutani (1), Megumi Takahashi (2), Satoru Oishi (2), Kumiko Shichijou (3), Hitoshi Miyaoka (2)</td>
<td>(1) Kitasato University Graduate School of Medical Sciences, (2) Department of Psychiatry, Kitasato University School of Medicine, (3) Clinical trial center, Kitasato University East Hospital</td>
</tr>
<tr>
<td>P4</td>
<td>Predictors of progression from mild cognitive impairment to Alzheimer’s disease in the placebo arm of a clinical trial population</td>
<td>Niels D.Prins (1), Wiesje M.Van der Flier (1), H.Robert Brashear (2), Frederik Barkhof (1,3), Philip Scheltens (1)</td>
<td>(1) Alzheimer Center and department of Neurology, VU University Medical Centre, Amsterdam, the Netherlands, (2) Janssen Alzheimer Immunotherapy Research and Development, South San Francisco, CA, USA (3) Alzheimer Centre, Department of Radiology, and Image Analysis Centre, VU University Medical Centre, Amsterdam, the Netherlands</td>
</tr>
<tr>
<td>P5</td>
<td>The SKT short cognitive performance test in patients with dementia: Cross-sectional and longitudinal correlations with activities of daily living in two independent clinical trials</td>
<td>R.Hoerr (1), H.Lehfeld (2), S.Schlaefke (1)</td>
<td>(1) Clinical Research Department, Dr. Willmar Schwabe GmbH &amp; Co. KG, Karlsruhe, Germany, (2) Department of Psychiatry and Psychotherapy, Nuremberg Hospital, Nuremberg, Germany</td>
</tr>
<tr>
<td>P6</td>
<td>Innovative Digital Patient Recruitment Strategies in Prodromal AD trials</td>
<td>Lynne Hughes (1), Amir Kalali (1), Cathy Vanbelle (1), Elisa Cascade (1)</td>
<td>Quintiles, Inc</td>
</tr>
<tr>
<td>P7</td>
<td>Cognitive impairment, dementia and «good performers»: prevalence in the population study «Invece.Ab»</td>
<td>Antonio Guaita (1), Simona Abbondanza (1), Mauro Colombo (2), Annalisa Davin (1), Gianluigi Forloni (3), Letizia Polito (1), Roberta Vaccaro (1), Eleonora Valle (1), Silvia Vitali (2), Virginia V Ferretri (4), Simona Villani (4)</td>
<td>(1) GolgiCenci Foundation, Abbiatgegrasso (Milan), Italy, (2) Geriatric Institute “C. Golgi”, Abbiatgegrasso (Milan), Italy, (3) Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milan, Italy, (4) Department of Health Sciences, Section of Medical Statistics and Epidemiology, University of Pavia, Pavia, Italy</td>
</tr>
<tr>
<td>P8</td>
<td>The Placebo Group Simulation Approach (PGSA): Its Validity when Applied to Data from Alzheimer Patients in the ADNI 1 Database</td>
<td>René Spiegel (1), Manfred Berres (2), Andreas U.Monsch (1)</td>
<td>(1) University Hospital, Department of Geriatrics, Memory Clinic, Basel Switzerland, (2) University of Applied Sciences Koblenz, RheinAhr Campus, Remagen Germany</td>
</tr>
<tr>
<td>P9</td>
<td>Intra-individual variability (IIV) vs. total scores as the target outcome in clinical trials</td>
<td>Rochelle E.Tractenberg (1,2), Futoshi Yumoto (2,3), Paul S.Aisen (4)</td>
<td>(1) Departments of Neurology, Biostatistics, Bioinformatics &amp; Biomathematics, and Psychiatry, Georgetown University Medical Center, Washington, D.C., USA, (2) Collaborative for Research on Outcomes and –Metrics, USA, (3) University of Maryland University College, College Park, MD, USA, (4) Department of Neurology, University of California, San Diego, La Jolla, CA, USA</td>
</tr>
<tr>
<td>P10</td>
<td>Review and Analysis of Rater Errors on the Neuropsychological Test Battery (NTB) in an International Alzheimer’s Disease Clinical Trial</td>
<td>Lisle Kingery (1), Jenn Cromer (1,2), Brian Merry (1), Alison Miner (1), Judy Jaeger (1), Amy Veroff (1), Paul Maruff (3)</td>
<td>(1) Cogstate, New Haven, CT, USA, (3) Hospital for Special Care, New Britain, CT, USA, (3) CogState, Melbourne, Victoria, Australia</td>
</tr>
</tbody>
</table>
Clinical Trials: Methodological aspects - Continued

P11 INROADS: International Registry of Alzheimer’s Disease Patients
RA. Stern (1), PN. Tarol (2), HM. Arrighi (3), LA. Lacey (4), GA. Rippon (5), V. Menon (6), MT. Ropacki (3)
(1) Boston University, Boston, MA, (2) Banner Alzheimer’s Institute, Phoenix, AZ, (3) Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA, (4) Janssen Alzheimer Immunotherapy, Dublin, Ireland, (5) Pfizer Inc, Collegeville, PA, (6) Outcome Sciences, Cambridge, MA

P12 Neuropsychiatric Syndromes in Mild versus Moderate AD: Factor Analysis from a Clinical Trial Population
Constantine Lyketsos (1), Susan Abushakra (2), Gerald Crans (2), Chito Hernandez (2), Sandrine Andreiue (3), Bruno Vellas (3)
(1) Johns Hopkins University, Baltimore, MD, USA, (2) Elan Pharmaceuticals, Inc., South San Francisco, CA, USA, (3) University of Toulouse, Toulouse, France

Clinical trials Assessment Tools

P13 Patient and carer views on clinical trials using immunotherapy for prodromal Alzheimer’s disease
Vanessa Lawrence (1), James Pickett (2), Joanna Murray (1)
(1) Institute of Psychiatry, King’s College London, UK, (2) Alzheimer’s Society, London, UK

P14 Can Screen to Baseline MMSE Variability in AD Clinical Trials Affect Primary Outcome Measurement?
David S. Miller (1), Yantui Xu (1), Priscilla Samuelson (1), David Henley (2), Gopalan Sethuraman (2), Karen Sundell (2)
(1) Bracket, Wayne, PA, USA, (2) Eli Lilly & Co., Indianapolis, IN, USA

P15 ADAS-Cog is an effective tool for Cognitive Research in Southeast Asia
Nagaendran Kandiah, Ivane Chew, Shan Huang, Amanda Ng
Department of Neurology, National Neuroscience Institute, Singapore

P16 National Institutional Review Board for Neurodegenerative Diseases (NIRB-ND) for the United States
Ara S. Khachaturian (1), Peter J. Snyder (2), Maria Carrillo (3), David S. Knopman (4)
(1) The Campaign to Prevent Alzheimer’s Disease by 2020 (PAD2020), Rockville, Maryland, USA, (2) Lifespan Hospitals & Alpert Medical School of Brown University, Providence, Rhode Island, USA, (3) The Alzheimer’s Association, Chicago Illinois, USA, (4) The Mayo Clinic & Alzheimer’s Disease Cooperative Study, Rochester, Minnesota, USA

P17 Assessment of consent ability in Alzheimer’s disease during research: a pilot study of a French questionnaire
Nathalie Philipp (1), Chloé Chauvet-Dalard (2), Isabelle Migeon-Duballet (3), Barbara Jung (1), Olga Uspenskaya (4), Hélène Mollon (5), Karim Bennys (2), Lynda Touati (2), Audrey Gabelle-Deloustal (2), Jacques Touchon (2,7), Benjamin Cretin (1), Marc Paccalin (3), Catherine Martin-Hunyadi (1), Frédéric Blanc (1), Jean-Christophe Weber (1)
(1) Strasbourg University Hospital, France, (2) Montpellier University Hospital, France, (3) Poitiers University Hospital, France, (4) IM2A, Pitité-Saléthire Hospital University, Paris, France, (5) Lyon University Hospital, France, (6) IRIST – EA 3424, Strasbourg University, France, (7) INSERM U1061, Montpellier, France

P18 The Memory and Attention Test (MAT): a computer-based test for studies in dementia
Georg Adler (1), Miriam Bektasn (1), Nadja Baumgart (2), Yvonne Lembach (1)
(1) Institut fuer Studien zur Psychischen Gesundheit (ISPG), Mannheim, Germany, (2) Dynamikos GmbH, Mannheim, Germany

P19 Establishing threshold scores and profiles of cognitive impairment for the Alzheimer’s Disease Assessment Scale (ADAS-Cog) for patients with probable Mild Cognitive Impairment (MCI)
C. Yavorsky (1, 2), G. DiClemente (1), M. Opler (2), A. Khan (2, 3), S. Jovic (2), B. Rothman (2)
(1) CROnos CCS, Hamilton, NJ, (2) ProPhase LLC, New York, NY, (3) Nathan S. Kline Institute for Psychiatric Research
SCIENTIFIC POSTERS

Clinical trials Assessment Tools - Continued

P20 Testing the dynamic model of Alzheimer’s disease in two European memory clinics
Giovanni B Frisoni (1), Anna Paola Prestia (1), Anna Caroli (1, 2), Wiesje M Van der Flier (3, 4), Rik Ossenkoppele (3, 5), Bart N M Van Berckel (6), Charlotte E Teunis (7), Philip Scheltens (3), Translational Outpatient Memory Clinic – TOMC - Working Group
(1) LENITEM – Laboratory of Epidemiology Neuroimaging and Telemedicine, IRCCS Centro San Giovanni di Dio FBF, Brescia, Italy, (2) Medical Imaging Unit, Biomedical Engineering Department, Mario Negri Institute for pharmaceutical research, Bergamo, Italy, (3) Alzheimer Center and dept of Neurology, VU University Medical Center, Amsterdam, The Netherlands, (4) Dept of Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, The Netherlands, (5) Dept of Nuclear Medicine and PET research, VU University Medical Center, Amsterdam, The Netherlands, (6) Dept of Radiology, VU University Medical Center, Amsterdam, The Netherlands, (7) Dept of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands

P21 ADAS-EXEC: A cognitive composite derived from the ADAS-cog and NTBA
John Harrison (1, 2), Jill Altman (3), Geoffrey Kempler (4), Dianne Angus (4), Caroline Herd (4), Steve Targum (5), Jeffrey Cummings (6), Craig Ritchie (2)

Therapeutic trials in AD

P24 Long-term administration of active immunotherapy CAD106 in Phase IIa open-label extension studies in Alzheimer Patients
(1) Novartis Pharma AG, Basel, Switzerland, (2) Indiana University, Indianapolis, USA, (3) Karolinska Universitetssjukhuset, Huddinge, Sweden, (4) Université de Bordeaux, France

P25 Evaluating the Cognitive Effects of Donepezil 23 mg/d in Moderate and Severe Alzheimer’s Disease: A Patient Subgroup Analysis
Marian Sabbagh (1, 2), Jeffrey Cummings (3, 4), Martin Farlow (5), Joan Mackell (6), Randi Fain (7)
(1) Banner Sun Health Research Institute, Sun City, AZ, USA, (2) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, (3) University of Utah, Salt Lake City, UT, USA, (4) Baylor College of Medicine, Houston, TX, USA, (5) Indiana University School of Medicine, Indianapolis, IN, USA, (6) Pfizer Inc, New York, NY, USA, (7) Elsion Inc., Woodcliff Lake, NJ, USA

P26 Donepezil 23 mg/d for Moderate to Severe Alzheimer’s Disease: Assessing Subdomains of the Severe Impairment Battery
Steven Ferris (1, 2), Jeffrey Cummings (3, 4), Martin Farlow (5), Marian Sabbagh (6), Joan Mackell (7), Randi Fain (8)
(1) Alzheimer Disease Center, New York University Langone Medical Center, New York, NY, USA, (2) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, (3) University of Utah, Salt Lake City, UT, USA, (4) Baylor College of Medicine, Houston, TX, USA, (5) Indiana University School of Medicine, Indianapolis, IN, USA, (6) Banner Sun Health Research Institute, Sun City, AZ, USA, (7) Pfizer Inc, New York, NY, USA, (8) Elsion Inc., Woodcliff Lake, NJ, USA

P27 Simvastatin versus atorvastatin: which is the optimal choice to prevent Alzheimer’s disease?
Saleta Sierra, Javier S Burgos
BioPharma Division, Neuron Bio, Parque Tecnológico de Ciencias de la Salud, Granada, Spain
### Therapeutic trials in AD - Continued

**P28** A Nicotinic-alpha-7 Partial Agonist as adjunctive therapy to stable Donepezil  
*Donna Masterman (1), Tari Awipi (1), Elizabeth Ashford (1), Stephane Nave (1), Kiseok Yoo (1), Bruno Vellas (2), Luca Santarelli (1)*  
(1) CNS DTA, F. Hoffmann-La Roche, Ltd., Basel, Switzerland, (2) Clinic of Internal Medicine and Gerontology, University Hospital Center, Toulouse, France

**P29** Effects of ELND005 (Scyllo-inositol) on Neuropsychiatric Symptoms (NPS) in Mild / Moderate AD: Correlations of ELND005 Exposures to Neuropsychiatric Outcomes in a 78-Week Phase 2 Study  
*Earvin Liang (1), Jonathan Wagg (2), Matthias Kurth (1), Susan Abushakra (1)*  
(1) Elan Pharmaceuticals, Inc., South San Francisco, CA, USA, (2) Pharsight/Cartara Corporation, St. Louis, MO, USA

**P30** The Study of Pharmacological Efficacy of Dry Mulberry Burirum-60 in Alzheimer's Disease  
*Buavaroon Srichaiku, Waraporn Sutthisa Hospital, Thailand*

**P31** Cerebrolysin, a novel drug for the treatment of Alzheimer's Disease. An Experimental Study using nanowired delivery  
*Hari S Sharma (1), Rudy J Castellani (2), Mark A Smith (3), Z Ryan Tian (4), Dafin F Muresanu (5), Herbert Mössler (6), Aruna Sharma (1)*  
(1) Cerebrovascular Research Laboratory, Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, University Hospital, Uppsala University, Sweden, (2) Department of Pathology, University of Maryland, Baltimore, MD, USA, (3) Department of Pathology, Case Western Reserve University, Cleveland, Ohio USA, (4) Department of Chemistry & Biochemistry, University of Arkansas Fayetteville, Fayetteville, AR, USA, (5) Department of Neurosciences, University of Medicine & Pharmacy, University Hospital, Cluj-Napoca, Romania, (6) Ever Neuro Pharma, Oberbargau, Austria

**P32** Implication of Integrative Treatments for Real-Life Geriatric Patients with Depression, Dementia and Multiple Chronic Diseases: A 60-Month Follow-Up of a Naturalistic Study  
*Gjumrakch Aliev (1,2), Valentin Bragin (3), Ramon Cacabelos (4)*  
(1) Department of Health Science and Healthcare Administration, Department of University of Atlanta, Atlanta, GA USA, (2) GALLY International Biomedical Research Consulting LLC, San Antonio, TX, USA, (3) Stress Relief and Memory Training Center, Brooklyn, New York, NY USA, (4) EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine & Camilo José Cela University, La Coruña, Spain

**P33** A pharmacogenetics-supported clinical trial to delay onset of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD)  
*Allen D. Roses (1,2), Kathleen A. Welsh-Bohmer (2), Daniel K. Burns (1), Carl Chiang (1), Donna G. Crenshaw (1,2), Michael W. Lutz (1,2), Craig A. Metz (1), Ann M. Saunders (1,2), Stephen Brannan (3), Manoj Malhotra (3)*  
(1) Zinfandel Pharmaceuticals, Inc., Durham, NC, USA, (2) Duke Bryan ADRC, Durham, NC, USA, (3) Takeda Global Research & Development Center, Inc., Deerfield, IL, USA

**P34** Cognitive stimulation and APOE genotype in non-demented elderly subjects: a randomized controlled study (RCT)  
*Gianluigi Forloni (1), Letizia Polito (2), Annalisa Davin (2), Simonab Abbondanza (2), Roberta Vaccaro (2), Eleonora Valle (2), Antonio Guaita (2), Mauro Colombo (3), Silvia Vitali (3), Virginia Valeria Ferretti (4), Simona Villani (4)*  
(1) Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milan, Italy, (2) Golgi-Cenci Foundation, Abbiategrasso (Milan), Italy, (3) Geriatric Institute “C. Golgi”, Abbiategrasso (Milan), Italy, (4) Dep. of Health Sciences, Biostatistics and Clinical Epidemiology unit, Pavia University, Pavia, Italy

**P35** TauRx Global Phase 3 Clinical Trial of Tau-Aggregation Inhibitor Therapy with LMTX (TM)  
*Claude M. Wischik*  
University of Aberdeen, UK, TauRx Therapeutics
### SCIENTIFIC POSTERS

**Fundamental Research for AD clinical trials**

**P36** Dopamine D2-agonist Rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer’s disease patients.
Alessandro Martorana (1), Giacomo Koch (2)
(1) Clinica Neurologica- Dipartimento di Neuroscienze, Centro di Riferimento per la Malattia di Alzheimer- Università di Roma, Italy, (2) Fondazione Santa Lucia IRCCS, Rome, Italy

**P37** Cellular and Animal Models for High Through-Put Screening of Therapeutic Agents for the Treatment of Diseases of Aging in General and Alzheimer’s Disease in Particular
Jordan L. Holtzman
Departments of Pharmacology and Medicine and Division of Environmental Health Sciences, University of Minnesota, Minneapolis, USA

**P38** Potential of Human analogue of Morris Water Maze in translational medicine and the assessment of therapeutic response
John Harrison (2,4,5), Jan Laczo (1,2), Manfred Windisch (2,3), Jakub Hort (1,2)
(1) Memory Disorders Clinic, Department of Neurology, Charles University in Prague, 2nd Medical Faculty and University Hospital Motol, Prague, Czech Republic, (2) Polyhymnia Translational Research, London, UK, (3) JSW-LifeSciences GmbH, Grazbach-Graz, Austria, (4) Meta Cognition Ltd., Killington, UK, (5) Dept. of Medicine, Imperial College, London, UK

**P39** Voluntary exercise suppresses enhanced tau pathology by high calorie diet in a tauopathy mouse model
Yasumasa Yoshiyama
Department of Neurology and Clinical Research Center, Chiba East National Hospital, Chiba 260-8712, Japan

**P40** Monoclonal antibody generation based on the humanized yeast model system: improving tau diagnostics
Jeff Van den Brande (1,2), Joëlle Rosseels (1), Peter Borghaef (3), Dirk Jacobs (2), Marleen Michels (1), Luc Buée (4), Fred Van Leuven (3), Eugeen Vanmechelen (2), Joris Winderickx (1)
(1) Functional Biology, KU Leuven, Heverlee, Belgium, (2) ADx Neurosciences, Ghent, Belgium, (3) LEGTEGG, KU Leuven, Belgium, (4) Inserm, U837, Alzheimer & Tauopathies, Lille, France; Université Lille Nord de France, JP Aubert Research Centre, IMPRT, Lille, France; UDSSL, Faculté de Médecine-Pôle Recherche, Lille, France; CHU-Lille, Lille, France

**P41** Examining start up for a multicenter clinical trial of neurosurgical administration of nerve growth factor gene transfer
Sarah Walter (1), Elizabeth Shaffer-Bacareza (1), Ronlyn Chavez (1), Kristin Woods (1), Genevieve Matthews (1), Paul Aisen (1), Joshua Grill (2)
(1) Alzheimer’s Disease Cooperative Study, University of California San Diego, La Jolla, CA, USA, (2) Mary S. Easton Center for Alzheimer’s Disease Research, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

**P42** Molecular dynamics simulations applying for designing compounds that can be used for treatment of Alzheimer’s disease
Maricarmen Hermández (1), Martha Rosales (2), Jose Correa Basurto (1)
(1) Laboratory of Molecular Modeling and Bioinformatics, Escuela Superior de Medicina, IPN, (2) Laboratory of Biophysics and Biocatalysis. Escuela Superior de Medicina, IPN
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>P43</td>
<td>Changes of Biological Markers and Brain PET Imaging and Clinical Effects of Memantine for Patients with Moderate to Severe Alzheimer’s Disease: a 24 Week Double-blind, Randomized, Placebo-Controlled Study</td>
<td>Shifu Xiao (1,2), Tao Wang (1,2), Qiu Huang (3), Kewei Chen (3,4), Eric Reiman (4)</td>
<td>(1) Geriatric Psychiatry Department, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China, (2) Alzheimer’s Disease and Related Disorder Center, Shanghai Jiao Tong University, Shanghai, China, (3) Med-X Institute, Shanghai Jiaotong University, Shanghai, China, (4) Banner Alzheimer’s Institute and Banner Good Samaritan Medical Center, PET Center, Phoenix, AZ, USA</td>
</tr>
<tr>
<td>P44</td>
<td>Organotypic hippocampal slices coupled with multi-electrode array: an innovative method to investigate neuroactive compounds in neurodegenerative disorders</td>
<td>Venceslas Duveau, Céline Bouysriees, Mélanie Langlois, Corinne Roucard</td>
<td>SynapCeLL SAS, Biopolis, 5 avenue du Grand Sablon, La Tronche, France</td>
</tr>
<tr>
<td>P45</td>
<td>Development and Application of a Mathematical Model of Modulation of CSF Aβ40 in Cerebrospinal Fluid after Treatment with γ and β-secretase inhibitors</td>
<td>Huub Jan Kleijn, Lei Ma, Marissa Dockendorf, Rik de Greef, John Palca, Jim Kost, Mark Forman, Michael Egan, Julie Stone</td>
<td>Merck Research Laboratories, Whitestone Station, NJ</td>
</tr>
<tr>
<td>P46</td>
<td>Definition of Harmonized Protocol for Hippocampal Segmentation</td>
<td>Marina Boccardi (1), Martina Bocchetta (1,2), Lianna Apostolova (3), Josephine Barnes (4), George Bartzokis (5), Gabriele Corbetta (1), Charles DeCarli (6), Leyla deToledo-Morrell (7), Michael Firbank (8), Rossana Ganzola (1), Lotte Gerttsen (9), Wouter Henneman (10), Ronald J. Killiany (11), Nikolai Malykhin (12), Patrizio Pasqualetti (2), Jens C.Pruessner (13), Alberto Redolfi (1), Nicolas Robitaille (14), Hilka Soininen (15), Daniele Tolomeo (1), Lei Wang (16), Craig Watson (17), Henrike Wolf (18), Simon Duchesne (14), Clifford R.Jack Jr (19), Giovanni B.Frisoni (1)</td>
<td>(1) LENITEM (Laboratory of Epidemiology, Neuroimaging and Telemedicine) IRCCS – S. Giovanni di Dio – Fatebenefratelli Brescia, Italy, (2) AFAr – Associazione Fatebenefratelli per la Ricerca, Rome, Italy, (3) Laboratoire of Neuroimaging, David Geffen School of Medicine, University of California, Los Angeles, CA, (4) Dementia Research Centre, UCL Institute of Neurology, University College London, London, UK, (5) Department of Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, (6) Department of Neurology, University of California, Davis, CA, (7) Department of Neurological Sciences, Rush University, Chicago, Illinois, (8) Institute for Ageing and Health, Newcastle University, Wolfson Research Centre, Newcastle, UK, (9) Karolinska Institute, Stockholm, Sweden, (10) Department of Radiology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands, (11) Department of Anatomy and Neurobiology, Boston University School of Medicine, (12) Department of Biomedical Engineering, Centre for Neuroscience, University of Alberta, Edmonton, Alberta, Canada, (13) McGill Centre for Studies in Aging, Department of Psychiatry, McGill University, Montreal, Quebec, Canada, (14) Department of Radiology, Université Laval and Centre de Recherche Université Laval – Robert Giffard, Quebec City, Canada, (15) Dept of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, (16) Northwestern University Feinberg School of Medicine, Department of Psychiatry and Behavioral Sciences, United States, (17) Wayne State University School of Medicine, D-University Health Center, St. Antoine, Detroit, MI, (18) Department of Psychiatry Research and Geriatric Psychiatry, Psychiatric University Hospitals, University of Zurich, Zurich, Switzerland, (19) Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN</td>
</tr>
<tr>
<td>P47</td>
<td>Robustness of Automated Hippocampal Volumetry across MR Field strengths and Same-Day Repeat Scans</td>
<td>Robin Wolz (1,2), Adam J.Schwarz (3), Peng Yu (3), Pal Cole (4), Daniel Rueckert (1,2), David Raunig (5), Derek Hill (1)</td>
<td>(1) IXICO Ltd, London, UK, (2) Imperial College London, UK, (3) Eli Lilly and Company, Indianapolis IN, USA, (4) Cole Consulting, NJ, USA, (5)Icon Medical Imaging, Warrington PA, USA</td>
</tr>
<tr>
<td>P48</td>
<td>Disentangling the normal aging from the pathological Alzheimer’s disease progression on structural MR images</td>
<td>Marco Lorenzi (1,2), Nicholas Ayache (2), Xavier Penne (2), Giovanni B Frisoni (1), and the Alzheimer’s Disease Neuroimaging Initiative (ADNI)</td>
<td>(1) IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy, (2) A Research project, INRIA Sophia antipolis, France</td>
</tr>
<tr>
<td>P49</td>
<td>Integrating Biomarkers in 12 AD Programs</td>
<td>Amir Kalali, Cathy Vanbelle, Roza Haydu, Lynne Hughes, Quintiles Inc.</td>
<td></td>
</tr>
<tr>
<td>P50</td>
<td>Contribution of the N400 event related potential in the study of the Primary Progressive Aphasia</td>
<td>Kriennenn Bonna (1), Elise Benattor (1), Gérard Rondouin (2), Sylvie Moritz-Gasser (1), Guillaume Schar (3), Jacques Touchon (1,4), Audrey Gabelle-Deloustal (1)</td>
<td>(1) Department of Neurology, Memory Research Resource Center for Alzheimer’s Disease, University Hospital of Montpellier, France, (2) Neurophysiology Unit, Department of Neurology, University Hospital of Montpellier, France, (3) Department of Neurology, University Hospital of Nîmes, France, (4) INSEMER U1061, Montpellier, France</td>
</tr>
</tbody>
</table>
### SCIENTIFIC POSTERS

#### Biomarkers/Imaging in AD clinical trials - Continued

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>P51</td>
<td>Supporting evidence of the AD biomarker dynamic model in patients with mild cognitive impairment</td>
<td>Samantha Galluzzi (1), Cristina Geroldi (2), Giovanni Amicucci (3), Luisella Bocchio-Chiavetto (4), Matteo Bonetti (5), Cristian Bonvicini (6), Maria Cotelli (7), Roberta Ghidoni (8), Barbara Paghera (9), Orazio Zanetti (2), Giovanni B Frisoni (1),</td>
<td>Translational Outpatient Memory Clinic Working Group (1), Laboratory of Epidemiology, Neuroimaging and Telemedicine, (2) Alzheimer’s Unit, (4) Neuropsychopharmacology Unit, (6) Genetics Unit, (7) Laboratory of the Neuropsychology Cognitive Neuroscience Unit, and (8) Proteomics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; (3) Service of Anesthesiology, Azienda Ospedaliera Mellino Mellini di Chiari, Brescia, Italy, (5) Neuroradiology Service, Istituto Clinico Città` di Brescia, Brescia, Italy, (9) Nuclear Medicine Service, Spedali Civili di Brescia, Brescia, Italy</td>
</tr>
<tr>
<td>P52</td>
<td>Mass Spectrometry Quantitation of Multi-component Protein Biomarker Panels of Alzheimer’s Disease</td>
<td>Emma LSchofield (1), Ian Pike (1), Stephan Jung (2), Hans Dieter Zucht (2), Stefan Seizler (2), Christopher Löhse (2), Malcolm A Ward (1)</td>
<td>Proteome Sciences plc, UK (1), Proteome Sciences R&amp;D GmbH &amp; Co. KG, Frankfurt/Main, Germany</td>
</tr>
<tr>
<td>P53</td>
<td>Investigating Tau and phospho-Tau moieties present within CSF to further biomarker development</td>
<td>Emma LSchofield (1), Claire L.Russell (1), Christopher Löhse (2), Thorsten Prinz (2), Malcolm A.Ward (1), Ian Pike (1)</td>
<td>Proteome Sciences plc, UK (1), Proteome Sciences R&amp;D GmbH &amp; Co. KG, Frankfurt/Main, Germany</td>
</tr>
<tr>
<td>P54</td>
<td>Quantification of cerebral glucose metabolism during normal aging: a comparison of cerebral metabolic rate and spm analysis</td>
<td>Scott Nugent (1,2), Sébastien Tremblay (1,3,4), Alexandre Castellano (1,2), Mélanie Fortier (1), Eric Turcotte (3,4), Tamas Fülöp (1,5), Michelle Allard (6), Stephen Cunnane (1,2,5)</td>
<td>(1) Research Center on Aging, Sherbrooke, QC, Canada, (2) Department of Physiology and Biophysics, Université de Sherbrooke, QC, Canada, (3) Department of Radiobiology and Nuclear Medicine, Université de Sherbrooke, QC, Canada, (4) Centre for Molecular Imaging, Sherbrooke, QC, Canada, (5) Department of Medicine, Université de Sherbrooke, QC, Canada, (6) Nuclear Medicine Service, Hôpital Pellegrin, UMR-CNRS-5227, EPHE, Bordeaux, France</td>
</tr>
<tr>
<td>P56</td>
<td>Measurement invariance in MRI-derived volumetrics, but not memory tests: implications for longitudinal research of neurodegenerative disease</td>
<td>RE.Tractenberg (1,2), Futoshi Yamamoto (2,3)</td>
<td>(1) Departments of Neurology, Biostatistics, Bioinformatics &amp; Biostatistics, and Psychiatry, Georgetown University Medical Center, Washington, D.C., USA, (2) Collaborative for Research on Outcomes and –Metrics, USA, (3) University of Maryland University College, College Park, MD, USA, (4) Department of Neurology, University of California, San Diego, La Jolla, CA, USA</td>
</tr>
<tr>
<td>P57</td>
<td>The distribution of Aβ42 among the different blood fractions might help in the early diagnosis of Alzheimer’s disease</td>
<td>Pedro Pesini (1,2), Virginia Pérez-Grijalba (1), Mercé Boada (3), Lluís Tarragó (3), Pablo Martínez-Lage (3), Itziar San-José (2), Manuel Sarasá (1,2)</td>
<td>(1) Arclon Biotech Ltd., Proteomic Laboratory, CIBIR Logroño, Spain, (2) Arclon Biotech Ltd., I + D Laboratory, Zaragoza, Spain, (3) Alzheimer Research Center and Memory Clinic. Fundació ACE. InstitutCatalà de NeurociènciesAplicades. Barcelona, Spain</td>
</tr>
<tr>
<td>P58</td>
<td>Validation of a multi-atlas segmentation technique for the quantification of hippocampal volume - Application as a selection criterion in clinical trials in Alzheimer’s Disease</td>
<td>H.J.Yu (1), L.Bracoud (1), J.Schaerer (1), D.Xu (1), F.Roccelle (1), B.Belaroussi (1), C.Pachai (1), C.DeCarli (2) and the Alzheimer’s Disease Neuroimaging Initiative</td>
<td>(1) BioClinica Inc., Lyon, France and Newtown, PA, USA, (2) University of California at Davis, CA, USA</td>
</tr>
<tr>
<td>P58 bis</td>
<td>Validation of a multi-atlas segmentation technique for the quantification of hippocampal volume – Application to ADNI I</td>
<td>J.Schaerer (1), L.Bracoud (1), F.Roccelle (1), H.J.Yu (1), B.Belaroussi (1), D.Xu (1), C.Pachai (1), C.DeCarli (2) and the Alzheimer’s Disease Neuroimaging Initiative</td>
<td>(1) BioClinica Inc., Lyon, France and Newtown, PA, USA, (2) University of California at Davis, CA, USA</td>
</tr>
</tbody>
</table>
Biomarkers/Imaging in AD clinical trials - Continued

**P59** Changes of Biological Markers and Brain PET Imaging and Clinical Effects of Memantine for Patients with Moderate to Severe Alzheimer’s Disease: a 24 Week Double-blind, Randomized, Placebo-Controlled Study
Shifu Xiao (1,2), Tao Wang (1,2), Qiu Huang (3,4), Kewei Chen (3,4), Eric Reiman (1,2,4)
(1) Geriatric Psychiatry Department, Shanghai Mental Health Center, Shanghai JiaoTong University School of Medicine, Shanghai, China, (2) Alzheimer’s Disease and Related Disorder Center, Shanghai JiaoTong University Shanghai, China, (3) Med-X Institute, Shanghai Jiaotong University, Shanghai, China, (4) Banner Alzheimer’s Institute and Banner Good Samaritan Medical Center, PET Center, Phoenix, AZ, USA

**P60** A new magnetic resonance-based approach to assessment of pathology in early Alzheimer’s disease
Timothy James (1), Kristin James (1), Lance Farr (1), Gareth Thomas (1), James Rafferty (1), Michael Brady (2), David Chase (1)
(1) Acutias Medical Ltd., Swansea, Wales, UK, (2) Dept. of Engineering Science, University of Oxford, UK

**P61** Evaluation of brain fuel metabolism during normal aging and in MILD Alzheimer’s disease (AD): comparison of 18F-Fluorodeoxyglucose with a novel PET ketone trace – Carbon –11 – Acetoacetate
Christian-Alexandre Castellano (1,2), Scott Nugent (1,2), Sébastien Tremblay (1,3), Mélanie Fortier (1), Nancy Paquet (3), Christian Bocti (4), Guy Lacombe (4), Éric Turcotte (3), Tamas Fulop (1,4), Stephen C Cunnane (1,2,4)
(1) Research Center on Aging, CSSS-IUGS, Sherbrooke, QC, Canada, (2) Department of Physiology and Biophysics, Université de Sherbrooke, QC, Canada, (3) Department of Radiobiology and Nuclear Medicine, Université de Sherbrooke, QC, Canada, (4) Department of Medicine, Université de Sherbrooke, QC, Canada

**P62** A dual tracer PET and MRI approach to study deteriorating brain fuel metabolism during aging
Stephen C.Cunnane (1,2,3), Alexandre Courchesne-Loyer (1,2), Maggie Roy (1,2), Scott Nugent (1,2), Christian A.Castellano (1,2), Sébastien Tremblay (1,4), Éric Turcotte (4), Tamas Fulop (1,3)
(1) Research Center on Aging, Sherbrooke, QC, Canada, (2) Department of Radiobiology and Nuclear Medicine, Université de Sherbrooke, QC, Canada, (3) Department of Radiobiology and Nuclear Medicine, Université de Sherbrooke, QC, Canada

**P63** An event- related potential index as a tool for the early diagnosis and drug development for Alzheimer’s Disease
Vasileios Papaliagkas (1,2), Magda Tsolaki (2), Vasileios Kimiskidis (2)
(1) Department of Neurology, Royal London Hospital, London, UK, (2) Third Neurological Clinic, Aristotle University of Thessaloniki, Greece

Nutrition and Alzheimer’s Disease

**P64** Supporting synapse formation and function in Alzheimer’s disease: mode of action of the specific nutrient combination Fortasyn™ Connect
John W Sijben, Martijn C de Wilde, Martine Groenendijk, Robert J Hageman, Patrick J Kamphuis, Laus M Broersen
Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands

**P65** Nutritional intervention with Fortasyn™ Connect: beneficial effects in experimental models of Alzheimer’s pathology and functional decline
Nick van Wijk (1), Martijn C. de Wilde (1), Almar A.M. Kuipers (1), Martin Balvers (1), Martine Groenendijk (1), John W. Sijben (1), Patrick J. Kamphuis (1,2), Henna Koivisto (3,4), Heikki Tanila (3,4), Diane Jansen (5,6), Valerio Zerbi (5,6), Amanda J.Kiliaan (5,6)
(1) Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands, (2) Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands, (3) A. I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland, (4) Neurology, Kuopio University Hospital, Kuopio, Finland, (5) Dept. Anatomy, Donders Centre for Neuroscience, RUMC, Nijmegen, The Netherlands, (6) Dept. Cognitive Neuroscience, Donders Centre for Neuroscience, RUMC, Nijmegen, The Netherlands

**P66** The Souvenaid Clinical Study Program for Alzheimer’s disease
Philip Scheltens (1), Raj C Shah (2), David A Bennett (2), Rico L Wieggers (3), Tobias Hartmann (4,5), Hilkka Soininen (6), Patrick JGH Kamphuis (3)
(1) Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands, (2) Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, Illinois, United States, (3) Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands, (4) Deutsches Institut für Demenz Prävention (DIDP), Neurodegeneration and Neurobiology, (5) Experimental Neurology, Homburg, Germany, (6) Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland
### SCIENTIFIC POSTERS

#### Nutrition and Alzheimer’s Disease - Continued

**P67**  
**Update of the LipiDiDiet study: a study on the effects of the medical food Souvenaid in subjects with prodromal AD**  
Yvonne Freud-Levi (1), Pieter Jelle Visser (2,3), Miia Kivipelto (4), Patrick JGH Kamphuis (5), Rico L Wieggers (5), Tobias Hartmann (6,7), Hilkka Soininen (8)  
(1) Department of NVS, Section of Clinical Geriatrics, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden, (2) Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, The Netherlands, (3) Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands, (4) Aging Research Center, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden, (5) Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands, (6) Deutsches Institut für DemenzPrävention (DIDP), Neurodegeneration and Neurobiology, (7) Experimental Neurology, Homburg, Germany, (8) Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland

**P68**  
**Combined nutrient enrichment induces changes in synaptic protein expression in vitro**  
Paul J Savelkoul (1), Almar A Kuipers (1), Andrea Goudriaan (2), Robert J Hageman (1), John W Sijben (1), Guus AB Smit (2), Mark HG Verheijen (2), Patrick J Kamphuis (1,3), Laus M Broersen (1)  
(1) Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands, (2) Dept. Molecular and Cellular Neurobiology, CNCR, VU University, Amsterdam, The Netherlands, (3) Utrecht Institute for Pharmaceutical Sciences (UIPS), University Utrecht, The Netherlands

**P69**  
**Alzheimer’s Diet Modification: A Web-based Nutrition Tracking System For Patient Management and Outcomes Research**  
Richard S. Isaacson, Reza D. Khan, Christopher N.Ochner  
(1) Department of Neurology, University of Miami Miller School of Medicine, Miami USA, (2) EvoxVris, NYC, USA, (3) Department of Psychology, Columbia University College of Physicians and Surgeons, NYC, USA

**P70**  
**Evidence on Diet Modification for Alzheimer’s disease and Mild Cognitive Impairment**  
Christopher N.Ochner (1), Dulce Barrios (2), Clement Lee (2), Christine E Greer (3), Richard S.Isaacson (3)  
(1)Columbia University, College of Physicians & Surgeons, NYC, USA, (2)Columbia University, Institute of Human Nutrition, NYC, USA, (3)University of Miami Miller School of Medicine, Miami, USA

**P71**  
**Souvenir II open-label extension study showed that Souvenaid was well-tolerated and suggests that memory performance continued to improve over 48 weeks**  
Philip Scheltens (1), Rafael Blesa (2), Marcel GM Olde Rikkert (3), Christine AF von Amim (4), Anke Bongers (5), John Harrison (6), John Sijben (5), Elio Scarpini (7), Frans R Verhey (8), Maurits F.J Vandewoude (9), Rico L Wieggers (5), Bruno Vellas (10), Patrick JGH Kamphuis (5), on behalf of the Souvenir II open-label extension study group  
(1) Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands, (2) Hospital de la Sta Creu i St Pau, Barcelona, Spain, (3) Alzheimer Centre Nijmegen, Radboud University Medical Centre Nijmegen, The Netherlands, (4) Department of Neurology, Ulm University, Ulm, Germany, (5) Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands, (6) Meta Cognition Ltd, Kilmington, UK & Imperial College, London, UK, (7) Ospedale Maggiore Poliambulante, University of Milan, Milan, Italy, (8) Alzheimer Centre Limburg, Maastricht University Medical Centre, The Netherlands, (9) University Centre for Geriatrics, Antwerp Hospital Network (ZNA), Campus St Elisabeth, Antwerp, Belgium, (10) Gerontopole, INSEERM U 1027, Toulouse, France

### Miscellaneous in clinical trials

**P72**  
**Face-name associations memory training during non-invasive brain stimulation improves memory in Alzheimer’s patients**  
Maria Cotelli (1), Rosa Manenti (1), Michela Petesi (1), Michela Brambilla (1), Sandra Rosini (1), Orazio Zanetti (1), Carlo Miniussi (1,3)  
(1) IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, (2) Centre for Brain Aging and Neurodegenerative Disorders, Neurology Unit, University of Brescia, Italy, (3) Department of Clinical and Experimental Sciences, National Neuroscience Institute, School of Medicine, University of Brescia Italy

**P73**  
**Physical exercise training in older adults diagnosed with mild to moderate dementia**  
Andrea Zamfirescu (1), Ana Capisizu (1), Mirea Sălăvă (2), Alexandru A. Capisizu (3), Aurel Romla (1)  
(1) University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania “St. Luca” Hospital, Clinic of Geriatrics, Bucharest, Romania, (2) National Academy of Physical Education and Sports, Bucharest, Romania, (3) Alexandru Obregia Hospital, Clinic of Neurology, Bucharest, Romania
<table>
<thead>
<tr>
<th>Post</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>P74</td>
<td>Cognitive impairment prevalence and correlations with subjective memory impairment: Findings from Brasov, Romania</td>
<td>Minerva Gurgu (1), Andreea Zamfirescu (2), Stroie Ana-Maria (3), Romila Aurel (1)</td>
<td>(1) University of Medicine and Pharmacy “ Carol Davila”, Bucharest, Romania, Department of Geriatrics, Emergency Hospital- Brasov, Romania, (2) Clinic of Geriatrics, “Sf. Luca” Hospital, Bucharest, Romania (3) Department of Geriatrics, Hospitalier Breton, Vannes, France</td>
</tr>
<tr>
<td>P75</td>
<td>Computerised cognitive testing can identify year by year declines in non-demented elderly aged 70 to 90 years</td>
<td>Keith A Wesnes (1,2), Brian K Saxby (3)</td>
<td>(1) Bracket Global, Goring-on-Thames, UK (2) Centre for Human Psychopharmacology, Swinburne University, Melbourne, Australia, (3) Newcastle University, Newcastle upon Tyne, UK</td>
</tr>
<tr>
<td>P76</td>
<td>The transition of cognitive decline from normal ageing to Mild Cognitive Impairment and Alzheimer’s disease.</td>
<td>Keith Wesnes (1,2), William Lenderking (3)</td>
<td>(1) Bracket Global, Goring, UK, (2) Swinburne University, Melbourne, Australia, (3) United BioSource, Boston, USA</td>
</tr>
<tr>
<td>P77</td>
<td>A cognitive task sensitive to dentate gyrus activity which has implications for assessing neurogenesis status in normal and pathological ageing</td>
<td>Keith A. Wesnes (1,2)</td>
<td>(1) Bracket Global, Goring on Thames, United Kingdom, (2) Swinburne University, Melbourne, Australia</td>
</tr>
<tr>
<td>P78</td>
<td>Use of the doll with Dementia-affected patients with behavior disturbances in a nursing home for Alzheimer patients.</td>
<td>Ivo Cilesi</td>
<td>Fondazione Santa Maria Ausiliatrice, Bergamo, Italy</td>
</tr>
<tr>
<td>P79</td>
<td>Therapeutic Virtual Train with Dementia-affected patients with behaviour disturbances in a nursing home for Alzheimer patients</td>
<td>Ivo Cilesi</td>
<td>Fondazione Santa Maria Ausiliatrice, Bergamo, Italy</td>
</tr>
<tr>
<td>P80</td>
<td>Assessment of an automated televigilance system on serious falls prevention in a dementia specialized care unit: the URCC</td>
<td>Isabelle Saulnier (1), Florent Lachal (1), Achille Tchalla (1), Justine Trimouillas (1), Florence Gourdeau-Nauche (2), Laurence Bernard-Bourzeix (1), Sophie Peyrichou (1), Sophie Fortuné (2), Thierry Dantoine (1)</td>
<td>(1) Geriatric Department, Limoges University Hospital, France, (2) Geriatric Department, Brive Hospital, France</td>
</tr>
<tr>
<td>P81</td>
<td>Robot assisted cognitive training can change the brain in the elderly: A single blind, randomized controlled trial of clinical efficacy</td>
<td>Geon Ha Kim (1), Seun Jeon (3), Byoung Hwa Lee (1), Han Soo Kim (3), Ju Hee Chin (1), Ga Young Kim (1), Hana Jeong (1), Jong Min Lee (3), Sang Won Seo (1), Ji Soo Shin (1), Hanna Cho (1), Young Noh (1), Sang Eon Park (4), Ho Jeong Kim (4), Cindy W.Yoon (1), Hee Jin Kim (1), Sung Tae Kim (2), Mun-Taek Choi (5), Mun Sang Kim (5), Jae Hong Lee (6), Duk L.Na (1)</td>
<td>(1) Department of Neurology and Radiology, (2) Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea, (3) Department of Biomedical Engineering, Hanyang University, Seoul, Republic of Korea, (4) Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Republic of Korea, (5) Korea Center for Intelligent Robotics at Korea Institute Science and Technology, Seoul, Republic of Korea, (6) Department of Neurology, Aisan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea</td>
</tr>
<tr>
<td>P82</td>
<td>Sepsis and Cognition</td>
<td>Catherine Widmann (1), Alexander Semmler (1,7), Torsten Okulla (1), Horst Urbach (3), Markus Kaiser (2,6), Guido Widman (4), Florian Mormann (4), Julia Weide (2), Klaus Flissbach (4), Thomas Klockgether (1), Andreas Hoefl (2), Frank Jessen (5), Christian Putensen (2), Michael T. Heneka (2)</td>
<td>(1) University of Bonn, Department of Neurology, (2) University of Bonn, Department of Anaesthesiology and Intensive Care Medicine, (3) University of Bonn, Department of Radiology/Neuroradiology, (4) University of Bonn, Department of Epileptology, (5) University of Bonn, Department of Psychiatry, (6) Department of Anaesthesiology, Medical College of Wisconsin, USA, current affiliation, (7) University of Zurich, Department of Neurology, Switzerland</td>
</tr>
</tbody>
</table>
SCIENTIFIC POSTERS

Miscellaneous in clinical trials - Continued

P83  ADCS EDC
Gustavo A. Jimenez-Maggioa, Ronald G. Thomas, Phuoc Hong, Paul S. Aisen, Department of Neurosciences, UCSD, USA

P84  High levels of CSF α-synuclein oligomers in Parkinson’s disease with dementia and dementia with Lewy bodies but not in Alzheimer’s disease
Omar M. A. El-Agnaf (1), Oskar Hansson (2,3,4), Sara Hall (2,3), Annika Öhrfelt (5), Shiji Varghese (1), Mohamed M. Qureshi (1), Abdulmonem Al-Hayani (6)
(1) Department of Biochemistry, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates, (2) Department of Clinical Sciences, Lund University, Sweden, (3) Neurology clinic, Skåne University Hospital, Sweden, (4) Memory clinic, Skåne University Hospital, Sweden, (5) Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Sweden, (6) Department of Anatomy, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

P85  Review of Safety of Spinal Catheter Placement for Intermittent Cerebrospinal Fluid Sampling in Clinical Trials on Healthy Volunteers
Steven Ramael (1), Luc Cavens (2), Anjana Dhar (1), Erika Wolters (1)
(1) SGS Life Science Services, Clinical Pharmacology Unit, Antwerp, Belgium, (2) Department of Neurosurgery, ZNA Middelheim, Antwerp, Belgium

P86  A New 26-week, Double-blind, Randomized, Placebo-controlled, Study of AC-1204 (caprylic triglyceride) in Mild to Moderate Alzheimer’s Disease: Presentation of Study Design
Rachelle Doody (1), James Galvin (2), Martin Farlow (3), Raj Shah (4), P. Murali Doraiswamy (5), Steven Ferris (2), Jean Zetland (6), Samuel Henderson (7), Richard S. Isaacson (8)
(1) Alzheimer’s Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, Houston, TX, (2) Alzheimer’s Disease Center, NYU Langone Medical Center, NYC, NY, (3) Alzheimer’s Disease Center, Indiana School of Medicine, Indianapolis, IN, (4) Rush University, Chicago, IL, (5) Department of Psychiatry, Duke University, Durham, NC, (6) Nestle Health Science, Lutry, Switzerland, (7) Accera Inc, Broomfield, CO, (8) Department of Neurology, University of Miami Miller School of Medicine, Miami, FL

P87  Prevention trials for Alzheimer’s Disease in non-demented subjects. A review of studies that use biomarkers for inclusion or as outcome
Daniela Bertens (1), Pieter Jelle Visser (1,2), Philip Scheltens (1)
(1) Alzheimer Centre, Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, (2) Alzheimer Centre, School for Mental Health and Neuroscience (MHeNS), University Medical Centre, Maastricht, The Netherlands

P88  Verbal Communication between Alzheimer’s patients and caregivers: improving and enhancing communication
Renné P. Alegria (1,2), Cláudia C. Santana (2), Célia P. Gallo (2), Mirian G. Bolso (2), Cássio M. C. Bottino (2), Maria Inês Nogueira (1)
(1) Neuroscience and Behavior, Institute of Psychology, University of Sao Paulo, (2) PROTER- Old Age Research Group, Institute of Psychiatry, Hospital das Clínicas, School of Medicine, University of Sao Paulo
Continuing Medical Education

Course Description:
Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s disease drugs is becoming essential to face up to this challenge. New pathways have been identified with biomarkers, facilitating novel trial designs for studies of tau-based therapies and other disease-modifying drugs including immunotherapy. However, methodological challenges continue to slow the development of specific new drug candidates. One of the objectives of the conference is to identify these hurdles and find ways to address them by bringing together world leaders in AD drug development to discuss solutions to the difficulties that have slowed the pace of progress, with a particular focus on clinical trial methodology.

Target Audience:
The target audience for CtaD2012 includes neurologists, psychiatrists and other clinicians and scientists involved in geriatric care, research, imaging and drug development for patients with Alzheimer’s disease and other neurodegenerative disorders. Other healthcare professionals who may benefit from this activity are clinical research coordinators, nurses, speech therapists and other AD and dementia occupational therapists, psychologists and neuropsychologists.

Course Learning Objectives:
During this event essential learning objectives will be covered so that at the end of the conference each participant will be able to:

a) Translate the significance to the drug development process of each individual phase of clinical trials from Phase I to Phase IV.


c) Implement in research studies: cognitive, clinical and biomarker measures that characterize the progression through the asymptomatic, prodromal and dementia phases of AD.

d) Interpret back valuable information on new upcoming molecules in order to educate fellow physicians and propose alternatives to patients.

e) List the novel methodologies or biomarkers essential in identifying predementia patients most at risk of developing AD.

f) List study findings, including safety, biomarker and clinical findings, presented at the conference underlying progress in understanding the amyloid hypothesis.

g) Assess different stages of AD, from the pre-symptomatic stages to severe dementia, to better plan and design future clinical trials.

h) Describe new composite outcome scores that optimize the power for measuring clinical disease progression for trials in a MCI and pre-MCI populations.

i) Describe and interpret sensitive biochemical (e.g. CSF A-beta, tau and phospho tau levels) and neurophysiological (e.g. QEEG, ERP) biomarkers of early AD detection.

j) Interpret ERP data in AD clinical trials and drug development for cohort selection and monitoring disease progression.

k) Identify and evaluate new methods for optimally scoring each patient’s test item responses and overall test performance, for determining the number of dimensions underlying the test’s performance, and for adjusting for sample bias effects.

l) Express appreciation for vertical integration and the impact it can have by improving knowledge transfer and drug development.
Needs assessments:

CTAD 2012 Scientific committee identified several practice gaps in designing and conducting AD Clinical Trials and developed the program to address these gaps, namely:

1. The need to appreciate the full spectrum of AD from an asymptomatic stage through dementia
2. The need for learning how dementia can affect specific population subgroups
3. The need to elucidate risk factors for AD and other dementias
4. The need to identify and avoid methodological errors in the design of multicenter and international clinical trials
5. The need for improved measurement of cognitive deficits
6. The need to keep up with scientific advances regarding biomarkers of AD pathologies.

Beyond these global practice gaps addressed throughout the conference other essential learning objectives will be covered so that at the end of the conference each participant will be able to understand:

- The importance of each individual phase of clinical trials from Phase I to Phase IV
- The relevance of neurotransmitters and cortical excitability in Alzheimer’s Disease pathology
- The cognitive, clinical and biomarker measures that characterize the progression through the asymptomatic, prodromal and dementia phases of AD.

Accreditation Statement:

The University of California, San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:

The University of California, San Diego School of Medicine designates this live activity for a maximum of **20.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cultural and Linguistic Competency Statement:

California Assembly Bill 1195 requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. It is the intent of the bill, which went into effect on July 1, 2006, to encourage physicians and surgeons, CME providers in the state of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population through appropriate professional development. The planners, speakers and authors of this CME activity have been encouraged to address issues relevant in their topic area. In addition, a variety of resources are available that address cultural and linguistic competency, some of which may be included in your syllabus or handout materials. Additional resources and information about AB1195 can be found on our website at [http://cme.ucsd.edu](http://cme.ucsd.edu).
Faculty List

Course Directors

Paul S. Aisen, MD
Alzheimer’s Disease Cooperative Study (ADCS)
Department of Neurosciences
UCSD School of Medicine
San Diego, USA

Jacques Touchon, MD, PhD
Chair of the Department of Neurology
Montpellier University Hospital
INSERM U1061
Montpellier, France

Bruno Vellas, MD, PhD
Toulouse University Hospital
Department of Neurology
Toulouse, France

Michael Weiner, MD
University of California at San Francisco,
San Francisco, USA

Francesco Amenta, MD, PhD
Centro RicercheCliniche,
Telemedicina e Telefarmacia,
Università di Camerino, Italy

Jennifer Barnett
Cambridge Cognition
University of Cambridge
Department of Psychiatry
Cambridge, UK

Randall Bateman, MD
Associate Professor, Neurology
Washington University School of Medicine
St. Louis, MO, USA

Karim Bennys, MD
Department of Neurology
Montpellier University Hospital
Montpellier, France

Karl Broich, MD
Federal Institute for Drugs and Medical Devices (BfArM)
Bonn, Germany

Luc Buée, PhD
Inserm U837 - Alzheimer &Tauopathies,
Faculty of Medicine, Research Department
Lille, France

Remy Cahn, MD
Global Regulatory Sciences
Bristol-Myers Squibb
Rueil, France

David M. Cash
Dementia Research Centre,
UCL Institute of Neurology,
University College London, UK

Jesse Cederbaum, MD
Global Clinical Research
Neuroscience
Bristol Meyers Squibb
Princeton, NJ, USA

Frédéric Checler
Molecular and Cellular Biology of Normal and Pathological Cerebral Aging
CNRS Sophia Antipolis, France

Nicola Coley
INSERM, U1027
Université de Toulouse III
Toulouse, France

Rachelle S. Doody, MD, PhD
Effie Marie Cain Chair in Alzheimer’s Disease Research
Director, Alzheimer’s Disease and Memory Disorders Center
Baylor College of Medicine-Department of Neurology
Houston, Texas USA

Bruno Dubois, MD, PhD
Neurological Institute,
UniversitySalpetriereHospital
Paris, France

Carole Dufouil, MD
Institut François Magendie
INSERM
Bordeaux, FRANCE

Michael F. Egan, MD
Merck & Co., Inc.
Whitehouse Station NJ, USA

UC San Diego

Michael Donohue
Division of Biostatistics & Bioinformatics,
Department of Neurosciences
UCSD School of Medicine

Dominic Holland
Alzheimer’s Disease Neuroimaging Initiative
UCSD School of Medicine

Visiting Faculty

Susan Abushakra MD
VP Global Development
AD Program Leader
Elan Pharmaceuticals
S. San Francisco, CA, USA

UC San Diego

Michael Donohue
Division of Biostatistics & Bioinformatics,
Department of Neurosciences
UCSD School of Medicine

Dominic Holland
Alzheimer’s Disease Neuroimaging Initiative
UCSD School of Medicine

Visiting Faculty

Susan Abushakra MD
VP Global Development
AD Program Leader
Elan Pharmaceuticals
S. San Francisco, CA, USA

UC San Diego

Michael Donohue
Division of Biostatistics & Bioinformatics,
Department of Neurosciences
UCSD School of Medicine

Dominic Holland
Alzheimer’s Disease Neuroimaging Initiative
UCSD School of Medicine

Visiting Faculty

Susan Abushakra MD
VP Global Development
AD Program Leader
Elan Pharmaceuticals
S. San Francisco, CA, USA
Faculty List

K.C. Fadem
Neuronetrix,
Louisville, KY, USA

Nick Fox, MD
UCL, Institute of Neurology,
London UK

Giovanni Frisoni, MD
LENITEM (Laboratory of Epidemiology,
Neuroimaging and Telemedicine)
IRCCS – S. Giovanni di Dio
Fatebenefratelli Brescia, Italy

Audrey Gabelle, MD
Department of Neurology, Memory center,
University Hospital Gui de Chauliac
Montpellier, FRANCE

Ezio Giacobini, MD, PhD,
Faculty of Medicine,
Department of geriatrics
University of Geneva, Switzerland

Terry Goldberg, PhD
Hofstra North Shore
LJ School of Medicine
Manahasset, NY, USA

John Harrison, PhD
Polyhymnia Translational Research
Metis Cognition, Ltd.
Dept. of Medicine, Imperial College,
London, UK

Suzanne Hendrix, PhD
Pentara Corporation,
Salt Lake City, UT USA

Dana C. Hilt, MD
EnVivo Pharmaceuticals
Watertown, MA USA

Jordan Holtzman MD, PhD
University of Minnesota,
Minneapolis, MN, USA

Jacques Hugon, MD, PhD
Hôpital Lariboisière
INSEERM U 839
Paris, France

Bruno Imbimbo, PhD
Research & Development
Chiesi Pharmaceuticals Inc.
Rockville, MD USA

Veronika Logovinsky, MD, PhD
Eisai Inc.
Neuroscience Product Creation Unit
Woodcliff Lake, NJ, USA

Marco Lorenzi
IRCCS San Giovanni di Dio
Fatebenefratelli, Brescia, Italy.
Asclepios research project
INRIA Sophia Antipolis, France

José A. Luchsinger, MD MPH
Associate Professor of Medicine and Epidemiology
at New York Presbyterian Hospital/Columbia University
Medical Center - Northern Manhattan Center of Excellence
in Minority Health and Health Disparities (NOCEMHD) at Columbia University
Division of General Medicine
New York, NY USA

Rupert McShane, MD, PhD
Cochrane Dementia and Cognitive Improvement Group
University of Oxford
United Kingdom

Thibault Mura, MD
INSERM, U1061, Neuropsychiatry
University of Montpellier I
University Hospital of Montpellier
INSERM, CIC 1001
Montpellier, France

Federico Palermiti
The Monegasque Association
for research on Alzheimer’s disease
Monte Carlo, MC

Harish C. Pant,
Senior Investigator
NINDS / NIH
Bethesda, MD, USA

Giulio Maria Pasinetti, MD, PhD
Department of Neurology
Mount Sinai School of Medicine
New York, NY USA

Pierre Payoux MD, PhD
Nuclear Medicine
Toulouse University Hospital France

Dan Perry
ACT-AD Coalition
Alliance for Aging Research
Washington, DC, USA

Michela Pievani
RCCS Fatebenefratelli
Brescia, Italy

Catherine Reed
Eli Lilly and Company Limited
Windlesham, UK
Faculty List

Stephen Salloway, M.D., M.S.
Director of Neurology and the Memory and Aging Program,
Butler Hospital
Professor of Clinical Neurosciences and Psychiatry
The Warren Alpert Medical School of Brown University
Providence, RI USA

Cristina Sampaio, MD, PhD
Laboratory of Clinical Pharmacology and Therapeutics,
Faculty of Medicine,
Lisbon, Portugal

Andrew Satlin, MD
Eisai Inc., Neuroscience Product Creation Unit,
Woodcliff Lake, NJ, USA

Bruno Scherrer, PhD
Bruno ScherrerConseil, St Arnoult, France

Philip Scheltens, MD, PhD
Alzheimer Centrum en afd.Neurologie
VU Medisch Centrum
Amsterdam, The Netherlands

Lon Schneider, MD,
Alzheimer’s Disease Research and Clinical Center
Department of Psychiatry Geriatric Studies Center
University of Southern California
Los Angeles, CA, USA

William R. Shankle, MS MD FACP
Shankle Clinic
Newport Beach, CA
Department of Cognitive Sciences,
UC Irvine, Irvine, CA, USA

Anders Sköldunger
Aging Research Center
KarolinskaIstitutet and Stockholm University
Stockholm, Sweden

Eric Siemers, MD
Alzheimer’s Disease Team
Eli Lilly
Indiana University School of Medicine
Indianapolis, IN, USA

Reisa Sperling, M.D.,
Associate Professor of Neurology,
Harvard Medical School
Director, Center for Alzheimer Research and Treatment
Brigham and Women’s Hospital
Massachusetts General Hospital
Boston, MA, USA

René Spiegel, MD
Memory Clinic,
Department of Geriatrics,
University Hospital
Basel, Switzerland

Mark Stemmler, MD,
University of Erlangen-Nuremberg,
Germany

Diane Stephenson, Ph.D
Coalition Against Major Diseases,
Critical Path Institute
Washington, DC USA

Robert M. Umek, PhD
Meso Scale Discovery
Gaithersburg, MD USA

Elisabeth CW van Straaten, MD, PhD
Department of Clinical Neurophysiology
VU University Medical Centre
Amsterdam, The Netherlands

Christopher van Dyck, MD
Professor of Psychiatry, Neurology, and Neurobiology
Director, Alzheimers Disease Research Unit
Yale University School of Medicine
New Haven, CT
USA

Thierry Voisin, MD, PhD,
Toulouse University Hospital
Toulouse, France

Keith Wesnes PhD
Bracket Global
Goring, UK
Swinburne University, Melbourne, Australia

Claude M. Wischik, PhD
TauRx Therapeutics

Robin Wolz, PhD
IXICO Ltd
Imperial College London
London, UK

Christian Yavorsky,PhD
CROnos CCS
Hamilton, NJ, USA
Disclosure summary

It is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms: 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

<table>
<thead>
<tr>
<th>Speaker Name</th>
<th>Name of Commercial Interest</th>
<th>Nature of Relevant Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Susan Abushakra</td>
<td>Elan Pharmaceuticals</td>
<td>Full-time Employee</td>
</tr>
<tr>
<td>Francesco Amenta</td>
<td>MDM SpA</td>
<td>Research support recipient</td>
</tr>
<tr>
<td>Jenny Barnett</td>
<td>Cambridge Cognition</td>
<td>Full-time Employee</td>
</tr>
</tbody>
</table>
  • Elan, Astra Zeneca  
  • Washington University  
  • C2N Diagnostics  
  • EnViVo Pharmaceuticals  
  • Novartis, Eisai, C2N Diagnostics, Medtronic | • Grants provided to Washington U  
  • Speakers’ bureau  
  • Full-time Employee/Royalties  
  • Stock options  
  • Member of the Advisory Board  
  • Consultant                                                                 |
<p>| Robert Brashear    | Janssen AI, LLC                                                                               | Full-time employee                                                                                                                                              |
| Remy Cahn          | Bristol Myers Squibb                                                                          | Full-time employee                                                                                                                                              |
| David Cash         | IXICO                                                                                         | Former Employee, stock options                                                                                                                                   |
| Jesse Cedarbaum    | Bristol Myers Squibb                                                                          | Full-time employee                                                                                                                                              |
| Rachel Doody       | Eli Lilly and Company                                                                         | Consultant via UCSD                                                                                                                                              |
| Bruno Dubois       | Eisai and Ipsen                                                                               | Consultant                                                                                                                                                       |
| Michael Egan       | Merck and Co.                                                                                 | Employee                                                                                                                                                         |
| KC Fadem           | Neuronetrix                                                                                   | President, board member, shareholder                                                                                                                               |</p>
<table>
<thead>
<tr>
<th>Speaker Name</th>
<th>Name of Commercial Interest</th>
<th>Nature of Relevant Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nick Fox</td>
<td>• Janssen Pharmaceuticals, Elan Pharmaceuticals, Pfizer and Wyeth Pharmaceuticals</td>
<td>• Participating in Phase 3 clinical Trial research with the Dementia Research Center</td>
</tr>
<tr>
<td></td>
<td>• Bristol-Myers Squibb, Eli Lilly Research Laboratories, AVID Radiopharmaceuticals Inc,</td>
<td>• Consultant</td>
</tr>
<tr>
<td></td>
<td>H. Lundbeck A/S, Janssen Alzheimer Immunotherapy Research Development</td>
<td>• Speaker and Advisor</td>
</tr>
<tr>
<td></td>
<td>• Frankfurt University Neurodegeneration Centre</td>
<td>• Co-chair of Research Advisory Council Executive Committee</td>
</tr>
<tr>
<td></td>
<td>• Alzheimer’s Society (UK)</td>
<td></td>
</tr>
<tr>
<td>John Harrison</td>
<td>Polynymnia Translational Sciences Ltd.</td>
<td>Shareholder and director</td>
</tr>
<tr>
<td>Suzanne Hendrix</td>
<td>Eisai</td>
<td>Consultant</td>
</tr>
<tr>
<td>Dana Hilt</td>
<td>Envivo Pharmaceuticals</td>
<td>Full-time employee</td>
</tr>
<tr>
<td>Bruno Imbimbo</td>
<td>Chiesi Pharmaceuticals</td>
<td>Employee</td>
</tr>
<tr>
<td>Earvin Liang</td>
<td>Elan Pharmaceuticals</td>
<td>Employee</td>
</tr>
<tr>
<td>Pierre Payoux</td>
<td>Eli Lilly and Co Bayer, GEHC</td>
<td>Advisory Board Member</td>
</tr>
<tr>
<td>Catherine Reed</td>
<td>Eli Lilly and Company Limited</td>
<td>Consultant</td>
</tr>
<tr>
<td>Stephen Salloway</td>
<td>• Janssen Alzheimer’s Immunotherapy, Baxter, Pfizer, BMS, Avid, Sanofi, Merck, Bayer</td>
<td>• Consultant</td>
</tr>
<tr>
<td></td>
<td>• Genentech, Roche, Bayer, GE</td>
<td>• Research support</td>
</tr>
<tr>
<td></td>
<td>• Athena</td>
<td>• Speaker</td>
</tr>
<tr>
<td>Andrew Satlin</td>
<td>Eisai</td>
<td>Full-time employee</td>
</tr>
<tr>
<td>Bruno Scherrer</td>
<td>Ipsen</td>
<td>Consultant</td>
</tr>
<tr>
<td>Lon Schneider</td>
<td>Eli Lilly, Elan, Johnson and Johnson, Takeda and Zinfandel, Allon, Merck, Roch, AstraZeneca,</td>
<td>Consultant</td>
</tr>
<tr>
<td></td>
<td>AC Immune</td>
<td></td>
</tr>
<tr>
<td>William Shankle</td>
<td>Medical Care Corporation</td>
<td>Chief medical officer and shareholders</td>
</tr>
<tr>
<td>Eric Siemers</td>
<td>Eli Lilly and Co</td>
<td>Employee and shareholder</td>
</tr>
<tr>
<td>Reisa Sperling</td>
<td>Pfizer</td>
<td>Consultant</td>
</tr>
<tr>
<td>Rene Spiegel</td>
<td>PlasimaGmbH</td>
<td>Co-founder and owner</td>
</tr>
<tr>
<td>Jacques Touchon</td>
<td>• Exhonit</td>
<td>• Honorarium and board member</td>
</tr>
<tr>
<td></td>
<td>• Ipsen</td>
<td>• Research support and board member</td>
</tr>
<tr>
<td>Robert Umek</td>
<td>MesoScale Diagnostics, LLC</td>
<td>Employer</td>
</tr>
<tr>
<td>Christopher van Dyck</td>
<td>• Bristol Myers Squibb, Janssen Pharmaceuticals, Pfizer</td>
<td>• Consultant and Grant support</td>
</tr>
<tr>
<td></td>
<td>• Eli Lilly, Baxter Pharmaceuticals, Medivation, Inc, Genentech, Inc, Roche Pharmaceuticals,</td>
<td>• Grant Support</td>
</tr>
<tr>
<td></td>
<td>Biogen Idec, Merck</td>
<td></td>
</tr>
<tr>
<td>Elisabeth van Straaten</td>
<td>Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialised Nutrition</td>
<td>Speaker honorarium</td>
</tr>
</tbody>
</table>
## Disclosure summary

<table>
<thead>
<tr>
<th>Speaker Name</th>
<th>Name of Commercial Interest</th>
<th>Nature of Relevant Relationship</th>
</tr>
</thead>
</table>
| Bruno Vellas | • Exhonit, Ipsen, Lilly, Pierre Fabre, Servier, TauRxTherapeutics, Avid  
• Eisai, Elan, Exhonit, GSK, Lilly, Medivation, Nestlé, Nutricia, Pfizer, Pierre-Fabre, Roche, Sanofi, Servier, TauRxTherapeutics, Wyeth  
• Astra Zeneca | • Grant recipient  
• Advisory Board member                                                                 |
| Keith Wesnes | Bracket Global                                                                                                   | Employee and stock holder  |
| Claude Wischik | TauRxTherapeutics                                                                                               | CEO  |
| Robin Wolz  | IXICO                                                                                                           | Part-time employee  |

The following have no relevant financial relationships to disclose:


The CME staff, meeting planners, planning committee and CME committee reviewers do not have any relevant financial relationships to disclose.

This educational activity may contain discussion of unlabeled and/or investigational uses of agents that are not approved by the FDA. Please consult the prescribing information for each product. The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, San Diego.
The Monegasque Association for the research on Alzheimer’s disease (AMPA), is delighted to welcome you to Monaco during the CTAD congress, 29 - 30 - 31 October 2012, which is under the high patronage of H. S. H. Prince Albert II of Monaco.

For the welcome cocktail reception, AMPA is honored to invite you to the emblematic Oceanographic Museum on Monday October 29th at 7:30 pm in the presence of H. S. H. Prince Albert II of Monaco. Bus departure at 7 pm from the Grimaldi Forum.

Built in 1910 on orders of Prince Albert I, the Oceanographic Museum is situated on the very edge of the “Rocher”, overlooking the Mediterranean Sea. It is one of the Principality’s architectural masterpieces, and hosts over 600 000 visitors a year and 6000 specimens of fish. Today, the Oceanographic Museum highly contributes to the country’s development, on scientific, economic and touristic terms, and is part of the Albert I, Prince of Monaco Institute, located in Paris.
Privileged Supporters

Clinical Trials on Alzheimer’s Disease (CTAD) would like to thank the following companies for their ongoing support helping CTAD meet its mission and goals.
Clinical Trials on Alzheimer's Disease

November 14-16, 2013
San Diego

http://www.ctad.fr